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ABSTRACT 
 
 
The 18kDa Translocator Protein (TSPO) was discovered as peripheral binding 
site for the benzodiazepine diazepam and initially named “Peripheral-type ben-
zodiazepine receptor” (PBR). This protein is mainly located at the contact sites 
between the outer and the inner mitochondrial membranes, and is strictly asso-
ciated with a number of proteins to form the mitochondrial permeability transi-
tion pore (MPTP). It is involved in a variety of biological processes including 
cholesterol transport, steroidogenesis, cell growth and differentiation, apoptosis 
induction, and regulation of immune functions. 
The expression of TSPO is ubiquitary in peripheral tissues (steroid producing 
tissues, liver, heart, kidney, lung, immune system), and in the central nervous 
system is mainly located in glial cells and in neurons. Many studies have re-
ported that the basal expression of TSPO is up-regulated in a number of neuro-
pathologies, including gliomas and neurodegenerative disorders (Huntington’s 
and Alzheimer’s diseases), in various forms of brain injury and inflammation, as 
well as in a variety of tumors; furthermore, a decrease in TSPO levels has been 
found in anxiety and mood disorders. 
Consequently, TSPO has been suggested as a promising diagnostic marker to 
image and measure the TSPO expression and distribution levels, and thus for 
evaluation of disease progression by means of specific fluorescent or radiolabeled 
ligands. In particular, PET imaging using TSPO ligands to label activated mi-
croglia offers quantitative measures of inflammation, and then can help to under-
stand the regional brain distribution, stage and severity of neuroinflammation. 
N,N-dialkyl-2-phenylindol-3-ylglyoxylamide derivatives were designed in 2004 
by Primofiore et al. as conformationally constrained analogues of the TSPO li-
gands indoleacetamides previously described by Kozikowski. These compounds 
have showed a high affinity for TSPO in the nanomolar to subnanomolar range 
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and a high selectivity for TSPO. Successively, Da Settimo et al. refined TSPO 
pharmacophore/topological model through the synthesis and the biological 
evaluation of novel indole derivatives.  
Evaluating a novel series of 2-phenylindol-3-ylglyoxylamides featuring a methyl 
substituent on the indole nitrogen, the same research group observed that the in-
sertion of the methyl group at the N1-position did not significantly influence 
TSPO binding. Therefore, these authors in collaboration with the research 
group of Pike et al. have developed novel radioligands for imaging brain TSPO 
with PET labeling the indole at the N1-position with the positron emitter car-
bon-11, and have indicated these compounds as promising new chemotype for 
development of novel TSPO radioligands as biomarkers of neuroinflammation.    
The aim of this work is to refine the TSPO pharmacophore/topological model 
through the synthesis and biological evaluation of a series of N,N-dialkyl-2-
phenylindol-3-ylglyoxylamides (I) bearing a polar group at the 4’-position of the 
2-phenyl ring (R3  NH2, COOH, OH), and of a series of N,N-dialkyl-2-(3-
thienyl)indol-3-ylglyoxylamides (II). These compounds have been synthesized as 
symmetrical amides featuring linear alkyl chains of different length on the amide 
nitrogen (n-propyl, n-butyl, n-hexyl) to evaluate any changes in the interaction 
with the lipophilic pockets of the pharmacophore. The TSPO affinity of interme-
diary compounds featuring a OCH3 and COOCH3 substituent in 4’-position has 
also been estimated.   
At the same time, envisaging the possibility to develop novel TSPO radioli-
gands, it has been evaluated the influence on the TSPO binding of the insertion 
of the methyl group at the N1-position: thus, has been prepared the N1-
methylated indoles and compared their Ki values with those of the N1-
unsubstitued parent compounds and the standard TSPO ligands Ro 5-4864 (2), 
PK11195 (5), and alpidem (6). 
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INTRODUCTION 
 
 
 
DISCOVERY OF THE TRANSLOCATOR PROTEIN (TSPO) 
 
 
In humans exist two different forms of benzodiazepine receptors: central benzo-
diazepine receptors (CBRs) and peripheral benzodiazepine receptors (PBRs).  
The first type (CBRs) is found in the brain and forms an allosteric site on the 
GABAA receptor complex. In fact, ligands acting at this allosteric site, such as 
diazepam and chlordiazepoxide, enhance the affinity of the -aminobutyric acid 
(GABA) toward the CBR and, in this way, influence chloride (Cl-) influx at the 
GABAA receptor pore, causing downstream effects on GABA-mediated inhibi-
tion.1 Different studies have shown benzodiazepines (BZs) acting on CBRs to be 
responsible for different GABAA-induced effects: BZs are used clinically as mus-
cle relaxants, anticonvulsants, anxiolytics and sedative-hypnotics.2   
The second type (PBRs) is first described in 1977 by Braestrup and Squires3 as 
an alternative binding site in non-neuronal tissue for the diazepam, a centrally 
acting benzodiazepine. It was named peripheral according to this tissue distribu-
tion and benzodiazepine receptor because BZs is the class of ligands by which PBR 
was discovered. However, multiple other names have been used to refer to this 
protein, including mitochondrial benzodiazepine receptor (MBR), mitochondrial di-
azepam binding inhibitor (DBI) receptor complex (mDRC), PK11195 binding sites 
(PKBs), isoquinoline binding protein (IBP), Omega3 (3) receptor.4   
In 2006 Papadopoulos and colleagues5 proposed the new name Translocator 
Protein 18 kDa, abbreviated TSPO. Although the name PBR was widely accepted 
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 mainly for historical reasons  in the scientific community, it didn’t take into 
account the new findings regarding its structure, subcellular roles and tissue dis-
tribution. It has also been shown that many ligands structurally different from 
BZs bind to this protein, which is not a receptor in the traditional sense, but ra-
ther a translocator of molecules such as cholesterol and protoporphyrins. Hence-
forth in this thesis work is adopted the abbreviation TSPO instead of PBR.      
During their pharmacological studies, Braestrup and Squires3 observed a specif-
ic binding of 3Hdiazepam to receptors in rat kidney, liver and lung, but at the 
same time noted that binding in non-neuronal tissue appeared to be very differ-
ent from the specific binding to brain membranes: first, while binding in kidney 
was associated with mitochondrial fraction, in brain it was associated with a 
membrane fraction; second, the affinity for receptors in kidney was lower than 
that for brain binding sites. 
Further studies demonstrated that TSPO is also present in nervous tissue and 
particularly in 1982 Marangos et al. confirmed that TSPO has a brain regional 
distribution distinct from that of CBR and that it is not linked to GABA-
regulated anion channels.6 In this key contribution, receptor binding was as-
sayed using diazepam which interacts only weakly with TSPO and the chlori-
nated analogue of diazepam Ro5-4864 (7-chloro-1,3-dihydro-1-methyl-5-(p-
chlorophenyl)-2H-1,4-benzodiazepine-2-one), which has a nanomolar affinity for 
TSPO (7.3nM)7 but a very low affinity for GABAA receptors (163 μM
8 in rat 
brain membranes) (Figure 1).  
N
N
Cl
O
N
N
Cl
O
Cl
Diazepam (1) Ro 5-4864 (2)
Figure 1. Diazepam (1), an anxiolytic drug with high affinity to CBR and Ro5-4864 (2), 
that differs from diazepam only by a chloride in the 5’ aromatic ring, substitution that 
dramatically reduces the activity at the CBR to TSPO.   
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Subcellular studies have confirmed the abundant mitochondrial localization of 
TSPO, although it has also been detected in smaller concentrations in other sub-
cellular compartments such as nuclei, Golgi apparatus, lysosomes, peroxisomes 
and plasma membrane. In 1986 Anholt and co-workers investigated the submi-
tochondrial localization of TSPO, using cytochrome oxidase as marker for the 
inner membrane and monoamine oxidase as outer membrane marker. Treating 
rat adrenal mitochondria with digitonin, a detergent able to separate the outer 
membrane from the inner membrane, they noticed that the release of TSPO in-
creased parallel to the release of monoamine oxidase and provided evidence for 
the association of TSPO with the mitochondrial outer membrane.9 
Later, with the understanding of molecular structure and functions of TSPO, it 
has been found that it is particularly concentrated at contact sites between the 
outer/inner mitochondrial membrane, sites also known as the mitochondrial 
permeability transition pore (MPTP).10    
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 MOLECULAR STRUCTURE OF TSPO 
 
 
Using photolabeling studies in 1988 Antkiewicz-Michaluk et al.11 identified the 
TSPO monomer, a protein with a molecular mass of 18 kDa, from the rat adrenal 
gland. It is a very hydrophobic and tryptophan-rich protein of 169 amino acids 
highly conserved throughout species. Three-dimensional modeling has revealed 
a structure with five transmembrane domains consisting of α-helices composed 
of 21 residues that span the entire membrane bilayer, with a carboxyl-terminal 
tail located outside the mitochondria and an amino terminal inside the mito-
chondria12,13 (Figure 2). Subsequently, topographic studies have indicate that 
the 18 kDa TSPO protein is organized in clusters of four to six molecules to 
form a single pore, reflecting the recognized function of transporter in the mito-
chondrial membrane.14    
 
Figure 2. Molecular structure of 18kDa TSPO and localization at the contact site be-
tween the outer and inner mitochondrial membrane. It is also shown some proteins as-
sociated with TSPO in the MPTP complex (VDAC, ANT and PRAX-1).12    
In 1992 McEnery et al. reported that TSPO is strictly associated in a trimeric 
complex with VDAC, a voltage-dependent anion channel of 32 kDa located at sites 
of contact between outer and inner mitochondrial membrane that acting as a 
channel allowing passage of small molecules and ions into the mitochondria, and 
ANT, adenine nucleotide translocase, a specific antiporter of 30 kDa, located in the 
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Figure 3. Hypothetical model of the interac-
tion between TSPO and PRAX-1.17  
inner mitochondrial membrane, for the exchange of ATP and ADP as part of 
oxidative phosphorylation.12,13 Together with other proteins, these three sub-
units constitute the mitochondrial permeability transition pore (MPTP).15  
Furthermore, it has been identified four cytosolic TSPO-associated proteins 
which most of time play an important role in the biological processes where 
TSPO is involved.  
p10 is the first cytosolic protein associated to TSPO identified, but whose bio-
chemical role has not been understood yet. It is a protein of 10 kDa that co-
immunoprecipited with 18 kDa TSPO using the isoquinoline carboxamide ra-
dioactive probe PK14105, a ligand selective for mitochondrial benzodiazepine re-
ceptors, to photolabel rat mitochondrial preparations.16   
PBR associated protein-1 (PRAX-1) is isolated, cloning and characterized by Ga-
liègue et al. in 1999.17 It is a protein of 1857 amino acids with a molecular mass 
of 240 kDa, discovered using the 
yeast two-hybrid screening strate-
gy. Exhibiting various domains in-
volved in protein-protein interac-
tion, such as proline-rich domains, 
leucine-zipper motifs and Src ho-
mology region 3-like (SH3-like) do-
domains, it has been suggested that 
PRAX-1 acts as an adaptor protein 
to recruit additional targets to the 
vicinity of TSPO so as to modulate 
its function. In addition, it was as-
sumed that a single PRAX-1 protein 
interacts with the C-terminal end 
(14 amino acids) of several mole-
cules of TSPO (at least two of them) 
(Figure 3).   
Another important protein functional associated to TSPO is Steroidogenic Acute 
Regulatory Protein (StAR), that mediates the flow of cholesterol from the outer to 
the inner mitochondrial membrane, permitting steroid formation in steroidogen-
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ic cells. Further studies indicated that StAR acts at the outer mitochondrial 
membrane and it is not needed to allow the entry of cholesterol into mitochon-
dria. Therefore, Hauet et al. suggest that TSPO and StAR work in concert to 
bring cholesterol into mitochondria and in particular TSPO serves as a gatekee-
per in cholesterol import into mitochondria and StAR plays the role of the hor-
mone-induced activator. 18,19 
PKA-associated protein 7 (PAP7) is a cytosolic protein with a molecular mass of 
52 kDa involved in the hormonal regulation of steroid formation, interacting 
with both the cytosolic RIα subunit of PKA and TSPO. Particularly, PAP7 tar-
gets the PKA isoenzyme, linked to increased steroid synthesis, which phosphory-
lating specific protein substrates induces the reorganization of TSPO topogra-
phy and function. 20 
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TSPO  DISTRIBUTION IN HEALTHY AND PATHOLOGICAL TISSUE 
 
 
The expression of TSPO is ubiquitary, although it considerably varies among 
tissues. An high density of TSPO is found in secretory and glandular tissues, 
such as adrenal glands, pineal glands, salivary glands, olfactory epithelium, 
ependyma and gonads. Intermediate levels of TSPO are detected in renal and 
myocardial tissues; in contrast, the brain (in particular glia, microglia and reac-
tive astrocytes) and liver express in normal condition relatively low levels of this 
protein. TSPO are also found among all human peripheral blood leukocyte sub-
sets, particularly in monocytes, polymorphonuclear cells and lymphocytes, and in 
mature human erythrocytes.13 
However, TSPO density can be modulated under a variety of physiological or 
pathological conditions. In fact, TSPO is generally highly expressed in steroido-
genic cells such as testicular and adrenocortical cells; elevated levels of TSPO, 
compared to healthy human tissues, have also been detected in cancerous tissues 
of the breast, ovary, colon, prostate, and brain glial tumor cells. It has also been 
supposed a correlation between TSPO levels and the metastatic potential of hu-
man breast cancer and brain gliomas.21 
TSPO is upregulated in brain injury and inflammation, in various neuropatho-
logical conditions (certain forms of epilepsy, stroke, herpes and HIV encephalitis) 
and neurodegenerative disorders (Alzheimer’s disease, multiple sclerosis, amyo-
trophic lateral sclerosis, Parkinson’s disease and Huntington’s disease). Moreo-
ver, TSPO levels are decreased in patients with generalized anxiety (detected in 
lymphocytes and platelets), panic, post-traumatic stress and obsessive-
compulsive disorders. Changes in TSPO expression have been observed during 
ischemia-reperfusion injury, indicating a role for TSPO in maintaining kidney 
function and renal protection.18,21,22 
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REGULATION OF STEROIDOGENESIS  
 
The most extensively characterized function of TSPO concerns its role in steroid 
biosynthesis. Two important observations suggest that TSPO plays an impor-
tant role in steroidogenesis: first, the location of this protein on the outer mito-
chondrial membrane and second, the extremely high density in steroidogenic en-
docrine tissues, such as adrenocortical cells and Leydig cells. Moreover, different 
publications report that TSPO ligands stimulate steroid biosynthesis in adrenal, 
placental, testicular, ovarian and glial systems.23,24 
The biosynthesis of steroids begins with the enzymatic transformation of choles-
terol into pregnenolone, which 
occurs through cholesterol 
side-chain cleavage by the cy-
tochrome P450scc (also known as 
CYP11A1) and auxiliary elec-
tron transferring proteins, loca-
lized on the matrix side of the 
inner mitochondrial membrane 
(Figure 4). Pregnenolone then 
leaves mitochondria to move to 
the endoplasmic reticulum, 
where it is transformed in the 
final steroid products.5,15,18 
The rate-limiting step is the translocation of cholesterol from the cellular stores 
across the aqueous intermembrane space to the inner mitochondrial membrane 
and P-450scc. The fundamental role of TSPO in this mitochondrial cholesterol 
transport and thus in steroids synthesis is supported by numerous data, and par-
FUNCTIONAL ROLES OF TSPO IN BIOLOGICAL PROCESSES  
Figure 4. TSPO facilitating mitochondrial cholesterol 
delivery regulates the synthesis of steroids.5  
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ticularly knockout and antisense experiments in vitro have demonstrated that 
down-regulation of TSPO causes a decrease in steroid synthesis.15,23,24  
The topographic study of TSPO in the mitochondrial membranes have also 
shown that after treatment of Leydig cells with a steroidogenesis stimulator, 
such as choriogonadotrophin hormone (hCG), there are various morphological 
changes, such as a formation of large complexes of 15-25 molecules of TSPO and 
a rapid reorganization of their localization in the mitochondrial membrane, as 
well as a rapid increase in TSPO ligand binding.15,23 
Moreover, amino acids deletion, site-directed mutagenesis and structural studies 
have permitted to identified a cholesterol recognition amino acid consensus (CRAC) 
sequence in the cytosolic carboxy-terminal domain of the TSPO that could be 
part of the binding site for the uptake and translocation of cholesterol (channel-
like interaction) through a channel delimited by five α-helixes of TSPO. However, 
for cholesterol delivery into mitochondria TSPO-mediated is also required the 
interaction of TSPO with StAR, as referred above, a protein acting as hormone-
induced activator.5,15,23  
It has been observed a relationship between steroid levels, TSPO levels and an-
xiety, principally due to the fact that neurosteroids are endogenous modulators 
of the GABAA receptor (Figure 5). In general TSPO levels, determined by radi-
oligand binding to platelets, decrease in patients with anxiety disorders. There-
fore, ligands binding to TSPO located in glial cells, such as N,N-dialchyl-2-
Figure 5. Schematic representation of TSPO-mediated regulation of neurosteroid bio-
synthesis and its role in neurological disorders.18   
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pheniylindol-3-ylglyoxylamides synthesized by Da Settimo et al.
25, provide the 
cholesterol necessary to restore neurosteroid synthesis and increase pregneno-
lone formation, which is then metabolize to form allopregnanolone, a potent al-
losteric modulator of the GABAA exerting anxiolytic effects. In this sense TSPO 
could be considering a promising target for the psychiatric disorders that involve 
dysfunction in steroid biosynthesis.18,26    
 
    REGULATION OF APOPTOSIS  
 
TSPO is a component of the mitochondrial permeability transition pore 
(MPTP), a multiprotein complex located at the contact site between the inner 
and outer mitochondrial membranes. MPTP plays an important role in the  
modulation of signaling pathways mediating apoptotic and necrotic cell death.  
The exact composition of the MPTP is not yet established, but it has been     
recognized various proteins implicated in pore formation and its regulation 
(Figure 6): an hexokinase, in the cytosol; a trimeric complex constituted by 
VDAC, ANC and TSPO (see “Molecular Structure of TSPO”); a creatine kinase in 
the intermembrane space and cyclophilin D in the matrix (for more information 
see ref. 27). 
MPTP allows the transfer of solutes, including ATP/ADP exchange, from the 
mitochondrial matrix to cytosol, through the VDAC/ANC conduit, and there-
fore facilitates the crossing of the highly impermeable mitochondrial inner  
  TSPO TSPO 
Figure 6. Schematic structure of the MPTP.13 
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membrane. This periodic transient increase in permeability by the MPTP allows 
the pumping of protons from the inner membrane by the electron transport 
chain and creates the transmembrane electrochemical gradient that drives ATP 
synthesis. 13,15   
Several factors cause the opening of the MPTP: high Ca2+ is the fundamental 
trigger but alone is not enough. Other important MPTP sensitizers are low ade-
nine nucleotide concentrations, high phosphate concentrations, oxidative stress 
and pro-apoptotic proteins such as Bcl-2. Pore opening leads to the dissipation of 
transmembrane electrochemical gradient, uncoupling of mitochondria and swel-
ling, resulting in  the release of cytochrome c and apoptosis inducing factor (AIF) in-
to the cytosol. Once in the cytosol, the first induces the caspase cascade ending in 
the destruction of cell nucleus, cytoskeleton and plasma membrane; the second 
principally leads to nuclear chromatin condensation, DNA fragmentation and 
then to cell death13. 
TSPO is an endogenous modulator of apoptotic process but the exact molecular 
events involved have not yet been definitively clarified. A possible mechanism for 
regulating the apoptotic pathway by TSPO is schematically illustrated in Figure 
7. In 2008 Veenman et al. 28 suggested that interaction between VDAC and 
TSPO is fundamental to initiate the 
mitochondrial apoptosis pathway. 
The intermediary agent between 
TSPO and VDAC was supposed to 
be provided by mitochondrial ROS 
(reactive oxygen species) generation 
under the control of the same 
TSPO. ROS lead first to dissocia-
tion of cytochrome c from oxidized 
cardiolipins located at the inner mi-
tochondrial membrane and, subse-
quently to its release in the cytosol 
via formation of a pore due to as-
semblage of VDAC molecules. 
Figure 7. TSPO regulation of the mitochon-
drial apoptosis pathway.28 
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Another possible mechanism was supposed in 2007 by Azarashvili et al. 
29 that 
provided evidence for TSPO involvement in MPTP opening, controlling the 
Ca2+-induced Ca2+ efflux and AIF release from mitochondria, important stage of 
initiation of programmed cell death. 
It has also been observed a modulation by TSPO of interactions between VDAC 
or ANT and pro-apoptotic or anti-apoptotic proteins (Bcl-2 and Bax, respective-
ly). 30 
Therefore, it has been designed TSPO ligands with pro-apoptotic effects acting 
as anticancer agents. In 2005 Chelli et al.31 proposed PIGA, a ligand chosen 
from the N,N-dialkyl-2-phenylindol-3-ylglyoxylamide series, as a novel pro-
apoptotic compound with therapeutic potential against glial tumours. TSPO-
binding ligands have also been widely explored as carrier for receptor-mediated 
drug delivery, such as TSPO ligandAra-C conjugates32 and Pt complexes.33       
       
    IMMUNOMODULATION  
 
TSPO plays an important role in host defense mechanisms and inflammatory re-
sponse. In fact, it is expressed in a wide range of cells involved in the regulation 
of the immune responses such as microglia, blood monocytes and leukocytes. It 
has been shown that some TSPO ligands, specifically benzodiazepines, have an 
immunosuppressive action, inhibiting the capacity of macrophages to produce 
ROS and inflammatory cytokines such as IL-1 (interleukin-1), TNFα (tumor ne-
crosis factor alpha) and IL-6, and regulating phagocyte oxidative metabolism re-
quired for elimination of foreign antigens.15 Furthermore, this anti-
inflammatory action TSPO-mediated is also due to its capacity of stimulate glu-
cocorticoid synthesis in steroidogenic organs and in local tissue damage.4   
In CNS, TSPO is primarily expressed in microglia and in astrocytes. Several 
studies have demonstrated that under conditions resulting in glial activation, 
such as inflammation and metabolic stress, basal levels of TSPO in these cells 
can increase in a time-dependent manner. This up-regulation of TSPO has been 
observed in traumatic, ischemic and chemically-induced brain injury, in neurode-
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generative disorders, i.e., in the temporal cortex from patients with Alzheimer’s 
disease and in the putamen of patients suffering from Huntington’s disease, in 
the epilepsy, multiple sclerosis and experimental autoimmune encephalomyeli-
tis.13  
Activation of microglia consists in migration to the site of damage, proliferation, 
production and release of potent neuroinflammatory cytokines (TNFα, IL-1β), 
arachidonic acid derivatives such as cyclooxygenase-2, excitatory amino acids, 
and ROS. As inflammatory responses mediated by the activation of microglia 
may aggravate in neuronal damage, and TSPO has proved to be a promising 
marker for activated microglia, it has attempted to develop specific TSPO li-
gands able to prevent or limit neuroinflammation or to label the same activated 
microglia to track the progression of neuroinflammation.15           
 
OTHER FUNCTIONS  
 
Other functions, some of which are linked to those previously mentioned, have 
been attributed to TSPO including protein import, important for membrane bio-
genesis and confirmed by the observation that TSPO is necessary for the import 
of StAR protein into mitochondria; TSPO binding of dicarboxylic porphyrin and 
transport into mitochondria have been reported as well as a relationship between 
TSPO and heme biosynthesis pathway; ion transport and calcium homeostasis, since it 
has been shown that TSPO regulates the Ca2+ flow into the cell. Furthermore, 
TSPO plays an important role in cellular respiration and mitochondrial oxidation, 
and affects cellular proliferation and differentiation in a number of cell types.
5 
Several studies have also shown that TSPO can modulate responses to viral in-
fections. In fact, pathogenic virus targets TSPO to inhibit dissipation of the 
transmembrane mitochondrial potential and prevents the release of cytochrome c, 
resulting in the blockade of apoptosis and overcoming of the host responses 
against viral infections.30      
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TSPO  ENDOGENOUS AND SYNTHETIC LIGANDS 
    
 
TSPO  ENDOGENOUS LIGANDS  
 
A wide variety of endogenous molecules with affinity for the TSPO and different 
chemical structures have been identified.  
Protoporphyrins (protoporphyrins IX, mesoporphyrins IX, deuteroporphyrins IX, 
hemin) exhibit a very high affinity for TSPO. As several steroidogenic tissues, 
such as the adrenal gland and testis, show high TSPO and porphyrin levels, it 
has been suggested a physiological role for the interaction of these two mole-
cules. Furthermore, having a plane of symmetry (Figure 8), these molecules 
could bind dimerized form of TSPO, confirming in this way the postulated two-
binding site model.15,24     
Another endogenous ligand is cholesterol, as previously reported discussing the 
fundamental role of TSPO in the regulation of cholesterol transport and thus in 
the steroidogenesis. Again it has been shown that a dimeric form of TSPO pos-
sesses an enhanced binding capacity to cholesterol.24     
In 1984 Corda et al. isolated and purified a neuropeptide able to inhibit diazepam 
binding to BZ binding site on brain membranes. This 11 kDa polypeptide, named 
DBI (diazepam binding inhibitor), is constituted by 86 amino acids and binds with 
OOH
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O
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  Figure 8. Chemical structures of protoporphyrin IX (3) and heme (4). 
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low affinity both TSPO and CBR, while a short fragment of DBI, triakontatetra-
neuropeptide, is more selective for TSPO. Furthermore, DBI promotes loading 
of cholesterol to the cytochrome P-450scc and stimulates steroidogenesis by di-
rectly interacting with TSPO.23,24     
Finally, anthralin, a 16 kDa protein that has been demonstrated interact with 
both TSPO and dihydropyridine binding site, and phospholipase A2 have also been 
proposed as endogenous ligands for TSPO.24     
 
TSPO  SYNTHETIC LIGANDS  
 
Synthetic TSPO selective ligands have been developed with the aim to deepen 
the knowledge of the exact pharmacological role of TSPO, to define its involve-
ment in several patho-physiological conditions and to establish the structural re-
quirements needed for an optimum of affinity.     
Initially, the most of these ligands have been designed starting from classical se-
lective CBR ligands, such as benzodiazepines, making the necessary structural 
modifies in order to shift the affinity toward TSPO. Until to date, the prototypic 
ligands, used as reference compounds in the development of TSPO pharmaco-
phore models and in SAR studies, are the benzodiazepine Ro 5-4864 (2) and the 
isoquinolinecarboxamide PK11195 (5), classified by LeFur and coworkers the 
first as a TSPO agonist or partial agonist and the second as an antagonist.15      
Subsequently, a number of diversified structures have been developed obtaining 
in some cases good results in term of affinity and selectivity, and leading to 
drawing various TSPO pharmacophore models useful for designing novel syn-
thetic derivatives. Therefore, the topology of the TSPO binding cleft has not yet 
been completely defined.4       
TSPO specific synthetic ligands do not have a typical shared structure and thus 
can be distinguished nine different classes of compounds (Figure 9). 
(1) In the class of benzodiazepines the selectivity toward the TSPO or CBR re-
sults very sensitive even to slight structural modifications: in fact, as de-
scribed earlier in Figure 1, in the case of Ro 5-4864 (2) the insertion of a 
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chlorine at the para position of the pendant phenyl rings of the diazepam, 
equipotent at the two receptors, shifts the selectivity toward TSPO. Ro 5-
4864 has been used in a number of studies aimed at characterizing TSPO, 
and particularly by Gavioli and colleagues to study the putative role of 
TSPO as a target for the treatment of psychiatric disorders.4      
(2) Benzothiazepines, a class of TSPO ligands featuring a 6,7 bicyclic nucleus, 
were initially developed by Campiani and coworkers as selective ligands for 
CBR and GABA receptor subtypes. Some pyrrolobenzothiazepines deriva-
tives possess an unexpected significant inhibitory activity at L-type calcium 
channels, equal to or higher than those of reference calcium antagonists such 
as verapamil and (+)-cis-diltiazem.
4       
(3) On the basis of pyrrolobenzothiazepine skeleton, the pyrrolobenzoxazepine 
scaffold has been developed, featuring the replacement of the endocyclic sul-
fur (S5) with an oxygen (O5), that increases affinity by 2-3 fold. Some of 
these compounds showed an high affinity toward the TSPO (Ki values in the 
low nanomolar-subnanomolar range) and the capacity to stimulate steroido-
genesis in mouse Y-1 adrenocortical cell line.4      
(4) Isoquinolinecarboxamide PK 11195 (5) is the first non-benzothiazepine li-
gand binding the TSPO with nanomolar affinity and it is widely used for 
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Figure 9. Structures of the some representative ligands of the most important 
classes of compounds selective for TSPO.    
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studies aimed to define and map the binding site. In 2008, Chelli et al. 
34      
showed that treatment of a human astrocytoma cell line (ADF) with PK 
11195 actives an autophagic pathway followed by apoptosis mediated by mi-
tochondrial potential dissipation. Moreover, has been showed that PK 11195 
has a multidrug resistance modulating activity increasing the efficacy of a 
daunorubicin treatment on human multidrug-resistant leukemia cell line in 
vitro by 5-7 fold and blocking p-glycoprotein efflux, a transporter whose ac-
tivity contributes to limit antitumor drug efficacy.30      
(5) Alpidem (6) can be considered the progenitor of the class of imidazopyri-
dines known to bind both TSPO and CBR with the nanomolar affinity (Ki 
0.5-7 nM and 1-28 nM, respectively).
4       
(6) Phenoxyphenylacetamide derivatives, such as DAA1097 (7), were designed 
by a process of molecular simplification involving the opening of the diaze-
pine ring of Ro 5-4864. Some compounds of this class of TSPO ligands have 
also showed potent anxiolytic properties in laboratory animals.4      
(7) Pyrazolopyrimidineacetamides, i.e. DPA714 (8), were first described by 
Selleri and coworkers as bioisosters of the imidazopyridines and thereby 
closely related to alpidem.4       
(8) Indoleacetamide derivatives, collectively named FGIN-1 (9), was developed 
by Kozikowski and colleagues as a new class of compounds binding with high 
affinity and selectivity for TSPO. 4 In a recent study SSR180575 (10), an in-
doleacetamide compound, was shown to have neuroprotective properties in 
different models of progressive degeneration of the PNS and CNS: precisely 
it promotes neuronal survival and repair following axotomy through the 
regulation of apoptosis of glial cells and/or the production of mediators such 
as neurosteroids, cytokines or other neurotrophic factors that support nerve 
survival.
30      
(9) Indol-3-ylglyoxylamides (for more information see next section).  
 
N,N-DIALKYL-2-PHENYLINDOL-3-YLGLYOXYLAMIDES  
 
In 2004 Primofiore et al.35 prepared and tested a series of N,N-dialkyl-2-
phenylindol-3-ylglyoxylamide derivatives I (Table 1) as TSPO ligands, de-
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signed as conformationally constrained analogues of the indoleacetamides of the 
FGIN (9) series previously described by Kozikowski and coworkers. They ob-
served that most of these compounds showed a high affinity for TSPO in the na-
nomolar to subnanomolar range and a high selectivity for TSPO over CBR. The 
TSPO/CBR selectivity was evaluated by binding studies using membranes from 
rat brain tissues and 3Hflumazenil as radioligand. For some of these TSPO li-
gands with high affinity, the ability to stimulate pregnenolone formation from 
rat C6 glioma cells was evaluated. 
In 2008 Da Settimo et al.25 refined TSPO pharmacophore/topological model 
through the synthesis and the biological evaluation of novel indole derivatives 
with the general formula I, bearing different combinations of substituents R1-R6.  
The SARs of these compounds were rationalized in light of a pharmaco-
phore/topological model of TSPO binding site made up of three lipophilic   
pockets (L1, L3 and L4) and a H-bond donor group (H1) (Figure 10). Specifical-
ly:  
1. the second carbonyl group of the oxalyl bridge engages an H-bond with the 
donor site H1; 
2. the two lipophilic substituents R1 and R2 (linear or ramified alkyl, arylalkyl 
group) on the amide nitrogen interact hydrophobically with the L3 or L4 li-
pophilic pockets; 
3. the 2-phenyl group establishes -stacking interactions within the L1 pocket.     
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Figure 10. TSPO pharmacophore/topological model.   
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In Table 1 has been reported the binding affinity of compounds Ia-Iaah (data 
taken from ref. 25, 35) and of the standard TSPO ligands Ro5-4864 (2), PK 
11195 (5) and alpidem (6), expressed as Ki values. 
It has been observed that, among the unsubstitued derivatives Ia-Im (R3  R4  
R5  R6  H), N-monosubstitued compounds Ia-Ib show the lowest affinity 
probably because they cannot occupy both the L3 and L4 lipophilic pockets. The 
N,N-disubstitued indolylglyoxylamides instead exhibit a high affinity and in par-
ticular compound Ig, bearing two n-hexyl groups, is the most potent, with a Ki of 
1,4 nM. Therefore, increasing the length of the linear N-alkyl groups has been 
observed an enhancement of affinity, due to the better filling of L3 and L4 lipo-
philic pockets. 35 
Subsequently, the three derivatives Id, Ie, Ig and Ij has been selected as leads for 
further affinity optimization efforts. It has been observed that4,25,35: 
 The insertion of an electron-donating lipophilic group, such as a methyl 
group (Idd-Igg), in the 4’-position (R3) of the 2-phenyl ring does not produce 
any gain in affinity respect to the parent unsubstitued compound. Introduc-
ing an electron-withdrawing substituent such as Cl, F, NO2 and CF3 (In-Icc), 
it has been instead obtained compounds with higher affinity, and among 
these ones, the N,N-di-n-hexyl derivatives Ip (Cl), It (F), Ix (NO2) and Ibb 
(CF3) have been revealed the most potent, with Ki values of o.37 nM, 0.55 
nM, 0.27 nM and 1 nM, respectively. These results suggest that the R3 subs-
tituent has to be electron-withdrawing to reinforce the putative -stacking 
interaction with an electron-rich aromatic ring within the L1 pocket.  
 The data of affinity of compounds Ihh-Iww bearing a substituent in the 5-
position of the indole nucleus (F, Cl, NO2, OCH3) suggest that R6 has to be 
electron-withdrawing and also very small for optimal binding, and only Ijj 
with a fluorine at the 5-position features these properties (Ki  0.37 nM). 
 The introduction of two halogens in both 4’- and 5-positions (Ixx-Iiii; Ivvv-
Iyyy) does not increase affinity in additive manner, but it has supposed a cor-
relation with the nature of the N,N-dialkyl chain.            
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 Substitutions at the 7-position of the indole nucleus (R5) with an electron-
withdrawing (Cl, Ijjj-Immm) or an electron-donating (CH3, Innn-Iqqq) li-
pophilic group do not produce any gain in affinity. 
 The binding data of asymmetrical N,N-dialkyl derivatives (Irrr-Iaah), de-
signed to probe the L3 and L4 lipophilic pockets at the TSPO binding site, 
indicate that the L3 and L4 pockets are probably different in their dimen-
sions, and that R1 and R2 have to be of different size to obtain the best-
performing substitution on the amide nitrogen. Therefore, an aromatic moie-
ty on R1/R2 substituents is equivalent to an aliphatic moiety of similar size 
in interacting with the two lipophilic pockets.        
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Table 1. TSPO binding affinity of N,N-dialkylindolylglyoxylamide derivatives Ia-Iaah.   
 
 
n R1 R2 R3 R4 R5 R6 
Ki (nM) or  
inhibition (%)c 
TSPOa CBRb 
Ro 5-4864      23.03.0  
PK 11195      9.300.5  
alpidem      0.5 – 7 1 – 28 
Ia (CH2)2CH3 H H H H H 81580 3293381 
Ib (CH2)3CH3 H H H H H 116799 12% 
Ic CH2CH3 CH2CH3 H H H H 43.04  
Id (CH2)2CH3 (CH2)2CH3 H H H H 12.21.0 16% 
Ie (CH2)3CH3 (CH2)3CH3 H H H H 7.50.7 3% 
If (CH2)4CH3 (CH2)4CH3 H H H H 16.02.0 3% 
Ig (CH2)5CH3 (CH2)5CH3 H H H H 1.40.2 10% 
Ih CH(CH3)2 CH(CH3)2 H H H H 1039.0  
Ii CH(CH3)CH2CH3 CH(CH3)CH2CH3 H H H H 17.02.0 5% 
Ij CH2CH3 CH2C6H5 H H H H 11.01.0  
Ik -(CH2)4- H H H H 2400125 4% 
Il -(CH2)5- H H H H 66530 3% 
Im -(CH2)6- H H H H 33.03.0 3% 
In (CH2)2CH3 (CH2)2CH3 F H H H 4.280.32 4.3% 
Io (CH2)3CH3 (CH2)3CH3 F H H H 2.400.81 0% 
Ip (CH2)5CH3 (CH2)5CH3 F H H H 0.370.13 0% 
Iq CH2CH3 CH2C6H5 F H H H 1.680.12 10% 
Ir (CH2)2CH3 (CH2)2CH3 Cl H H H 4.650.52 14% 
Is (CH2)3CH3 (CH2)3CH3 Cl H H H 1.000.27 0% 
It (CH2)5CH3 (CH2)5CH3 Cl H H H 0.550.19 4.2% 
Iu CH2CH3 CH2C6H5 Cl H H H 1.300.15 7.3% 
Iv (CH2)2CH3 (CH2)2CH3 NO2 H H H 0.950.1  
Iw (CH2)3CH3 (CH2)3CH3 NO2 H H H 0.230.07  
N
N R2
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I
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(table 1) contd… 
n R1 R2 R3 R4 R5 R6 
Ki (nM) or  
inhibition (%)c 
TSPOa CBRb 
Ix (CH2)5CH3 (CH2)5CH3 NO2 H H H 0.270.10  
Iy CH2CH3 CH2C6H5 NO2 H H H 0.550.02  
Iz (CH2)2CH3 (CH2)2CH3 CF3 H H H 1.690.2  
Iaa (CH2)3CH3 (CH2)3CH3 CF3 H H H 1.160.1  
Ibb (CH2)5CH3 (CH2)5CH3 CF3 H H H 1.00.1  
Icc CH2CH3 CH2C6H5 CF3 H H H 1.00.1  
Idd (CH2)2CH3 (CH2)2CH3 CH3 H H H 5.500.98  
Iee (CH2)3CH3 (CH2)3CH3 CH3 H H H 3.800.91  
Iff (CH2)5CH3 (CH2)5CH3 CH3 H H H 1.600.13  
Igg CH2CH3 CH2C6H5 CH3 H H H 2.640.1  
Ihh (CH2)2CH3 (CH2)2CH3 H H H F 2.670.48  
Iii (CH2)3CH3 (CH2)3CH3 H H H F 4.000.15  
Ijj (CH2)5CH3 (CH2)5CH3 H H H F 0.370.12  
Ikk CH2CH3 CH2C6H5 H H H F 1.330.2  
Ill (CH2)2CH3 (CH2)2CH3 H H H Cl 2.800.3 10% 
Imm (CH2)3CH3 (CH2)3CH3 H H H Cl 4.910.4 13% 
Inn (CH2)5CH3 (CH2)5CH3 H H H Cl 58.46 3% 
Ioo CH2CH3 CH2C6H5 H H H Cl 4.60.5  
Ipp (CH2)2CH3 (CH2)2CH3 H H H NO2 20.22.02 0% 
Iqq (CH2)3CH3 (CH2)3CH3 H H H NO2 21.62.15 1% 
Irr (CH2)5CH3 (CH2)5CH3 H H H NO2 30.39.15 0% 
Iss CH2CH3 CH2C6H5 H H H NO2 18.30.15 0% 
Itt (CH2)2CH3 (CH2)2CH3 H H H OCH3 32845 8.6% 
Iuu (CH2)3CH3 (CH2)3CH3 H H H OCH3 65.23.4 8.8% 
Ivv (CH2)5CH3 (CH2)5CH3 H H H OCH3 35.58.7 7.2% 
Iww CH2CH3 CH2C6H5 H H H OCH3 69.53.6 5.7% 
Ixx (CH2)2CH3 (CH2)2CH3 F H H Cl 2.830.08 14% 
Iyy (CH2)3CH3 (CH2)3CH3 F H H Cl 3.050.45 17% 
Izz (CH2)5CH3 (CH2)5CH3 F H H Cl 7.751.55  
Iaaa CH2CH3 CH2C6H5 F H H Cl 4.010.26 9.7% 
Ibbb (CH2)2CH3 (CH2)2CH3 F H H F 6.731.39  
Iccc (CH2)3CH3 (CH2)3CH3 F H H F 4.360.05  
Iddd (CH2)5CH3 (CH2)5CH3 F H H F 0.950.1  
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(table 1) contd… 
n R1 R2 R3 R4 R5 R6 
Ki (nM) or  
inhibition (%)c 
TSPOa CBRb 
Ieee CH2CH3 CH2C6H5 F H H F 1.670.37  
Ifff (CH2)2CH3 (CH2)2CH3 Cl H H Cl 0.620.06 5% 
Iggg (CH2)3CH3 (CH2)3CH3 Cl H H Cl 1.90.2 0% 
Ihhh (CH2)5CH3 (CH2)5CH3 Cl H H Cl 5.80.6 3% 
Iiii CH2CH3 CH2C6H5 Cl H H Cl 3.330.3  
Ijjj (CH2)2CH3 (CH2)2CH3 H H Cl H 14.01.5 0% 
Ikkk (CH2)3CH3 (CH2)3CH3 H H Cl H 3.400.3 1% 
Illl (CH2)5CH3 (CH2)5CH3 H H Cl H 2.40.3 0% 
Immm CH2CH3 CH2C6H5 H H Cl H 5.00.4 0% 
Innn (CH2)2CH3 (CH2)2CH3 H H CH3 H 25.03.0  
Iooo (CH2)3CH3 (CH2)3CH3 H H CH3 H 6.00.6  
Ippp (CH2)5CH3 (CH2)5CH3 H H CH3 H 1.900.1  
Iqqq CH2CH3 CH2C6H5 H H CH3 H 2.300.2  
Irrr CH3 CH2CH3 H H H H 940120 15% 
Isss CH3 (CH2)3CH3 H H H H 53.34.0  
Ittt CH3 (CH2)4CH3 H H H H 12.11.0  
Iuuu CH2CH3 (CH2)3CH3 H H H H 12.61.0  
Ivvv CH3 CH2CH3 Cl H H Cl 9.541.29 15% 
Iwww CH3 (CH2)3CH3 Cl H H Cl 0.150.02  
Ixxx CH3 (CH2)4CH3 Cl H H Cl 0.180.02  
Iyyy CH2CH3 (CH2)3CH3 Cl H H Cl 0.360.04  
Izzz CH3 CH2C6H5 H H H H 12.01.0  
Iaab CH3 CH2C6H5 F H H H 1.80.1  
Iaac CH3 (CH2)3CH3 Cl H H H 111.0  
Iaad CH3 (CH2)4CH3 Cl H H H 3.40.4  
Iaae CH2CH3 (CH2)3CH3 Cl H H H 3.60.4  
Iaaf CH3 (CH2)3CH3 H H H Cl 3.90.5  
Iaag CH3 (CH2)4CH3 H H H Cl 3.60.5  
Iaah CH2CH3 (CH2)3CH3 H H H Cl 1.80.2  
a The concentration of tested compounds that inhibited 3HPK 11195 binding to rat 
kidney mitochondrial membranes (IC50) by 50% was determined with six concentrations 
of the displacers, each performed in triplicate. Ki values are the mean  SEM of three de-
terminations. b The inhibition percent of 3Hflumazenil specific binding at 10 μM of 
the compound are the mean  SEM of five determinations. Ki values are the mean  
SEM of three determinations. c Data take from ref. 25, 35.        
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MOLECULAR PROBES FOR RECEPTOR CHARACTERIZATION 
  
Diagnostic imaging is referred to different imaging modalities and technologies, 
such as: 
 Radiography; 
 Nuclear Imaging:  
o PET (Positron Emission Tomography);  
o SPECT (Single Photon Emission Computed Tomography); 
o PET/CT (PET/Computed Tomography combination).  
 Magnetic Resonance Imaging (MRI); 
 Optical Imaging: 
o fluorescence;  
o near-infrared or NIR. 
 Diagnostic Ultrasounds.  
Some of these imaging methods are based on use of molecular probes and for this 
reason can be called “molecular imaging” modalities. Molecular probes can be re-
ferred to radiolabelled molecules or fluorescent ligands designed for in vitro or in 
vivo application, able to form covalent bindings with apposite constituents of re-
ceptor (affinity labels) and therefore useful for determination and characterization 
of a receptor by various chemical-physical techniques.  
Molecular probes generally consist of two parts:36  
1. a molecular structure (vector, vehicle, ligand), that defines the biological cha-
racteristics and is responsible for chemical and biochemical interactions with-
in the living organism, influencing in this way pharmacokinetic and pharma-
codynamic parameters; 
PET  USING TSPO  RADIOLIGANDS 
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2. a radioactive nuclide or a fluorophore group, responsible for a signal detecta-
ble outside of the organism for visualization with nuclear medical methods or 
fluorescent spectroscopy.  
Since they are chemically indistinguishable from their non-radioactive counter-
parts, molecular probes either interact directly with specific target sites and 
processes (substrates for enzymes, ligands for receptors or transporters) or take 
part directly in metabolic processes. For these reasons they can be used for in vi-
tro or in vivo visualization, characterization and quantification of biological 
processes at the cellular and subcellular level.36 
Molecular imaging is also a non-invasive biomedical instrument useful for the di-
agnosis and monitoring of cardiac pathology, different forms of cancer and neu-
rological diseases. Imaging methods also allows monitoring the progression of a 
pathology in a specific patient, permitting an approach of personalized therapy 
and visualizing a pathological change on the molecular level resulting in abnor-
mal function long before morphological manifestation.36 
               
MOLECULAR PROBES FOR TSPO 
 
As earlier referred, the density of TSPO is greatly increased in several human 
pathologies, including gliomas and neurodegenerative disorders, such as Hun-
tington’s and Alzheimer’s diseases, as well as in various forms of brain injury and 
inflammation. TSPO is also up-regulated in neuroinflammatory conditions me-
diated by microglial activation. In fact, in the healthy CNS microglia exists in a 
quiescent state, but upon “activation” in response to brain injury undergo mor-
phological changes including shortening of cellular processes and enlargement of 
their soma (“amoeboid” phenotype).
37 Changes in TSPO levels have also been 
detected in patients affect by generalized anxiety, panic, post-traumatic stress, 
obsessive-compulsive disorders, and separation anxiety. 38   
Consequently, TSPO has been suggested as a promising diagnostic marker to 
image and measure the TSPO expression and distribution levels in living cells, 
isolated tissues, or living subjects, and then for evaluation of disease progression 
by mean of specific fluorescent or radiolabeled ligands. 
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PET imaging using TSPO ligands to label activated microglia offers quantita-
tive measures of inflammation and then can help to understand the regional 
brain distribution, stage and severity of neuroinflammation: for these reasons, 
can be considered a valuable tool to determine individual approaches to treat-
ment of disease. 38   
Fluorescent ligands is a safer alternative to radioligands for investigating the lo-
calization and the expression level of TSPO. In 2010 Taliani and coworkers39 
developed novel potent, selective and irreversible fluorescent probes introducing 
a NBD-fluorophore (7-nitrobenz-2-oxa-1,3-diazol-4-yl) and an electrophilic iso-
thiocyanato group on the 2-phenylindolylglyoxylamide scaffold.   
 
IMAGING USING PET 
 
One of the most important imaging technique in the field of nuclear medicine, 
able to detect nanomolar metabolic variations, is Positron Emission Tomography 
(PET). Originally used primarily as a research tool, PET has also had an increa-
singly important clinical role. In particular there are four major areas of clinical 
application: oncology (diagnosis and monitoring of tumor, follow up therapy, 
tumor prognosis evaluation), cardiology (metabolism and myocardial viability), 
neurology (epilepsy, schizophrenia, Parkinson, Alzheimer) and psychology (“sen-
sorial emotional images”). 36    
PET is a radiotracer imaging technique which uses small amounts - generally 
picomolar concentrations thus not having any effect on the process being studied 
- of tracer compound labeled with positron-emitting radionuclides (called radio-
pharmaceutical or radiotracer) to help in the diagnosis of disease. Therefore, in 
PET short-lived radioactive drug emitting gamma rays is introduced in the sub-
ject of the study, either by injection or inhalation of a gas, and after an appropri-
ate uptake period its concentration in tissue is measured by a PET scanner, 
which produce an image showing its distribution in the body. 40   
PET looks at physiological processes rather than anatomical structures and then 
gives only functional information. Consequently, it may be difficult to accurately 
localized anatomic structures or lesions that exhibit abnormal radiotracer accu-
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mulation. This limitation can be overcome using PET/CT combination, which 
integrates the functional tissue information, that is provided by PET exam with 
the anatomical information, that can be obtained by structural imaging methods 
such as computed tomography (CT) exam, into one single exam. 41   
T H E  P H Y S I C A L  P R I N C I P L E S  O F PET 
 
All the positron emitters have proton-rich nuclei, and, in an attempt to stabilized 
themselves by getting rid of the excess protons and gaining neutrons in lieu, 
they may decay via positron emission or electron capture, both of which are isobaric 
decay processes.
41    
In Table 2 are showed some isotopes which decay via positron emission.  
Table 2. Properties of commonly used positron emitting radio-isotopes.40    
The positron is an antimatter electron, having the same mass but a positive 
charge. Schematically, the positron decay process can be represented by: 
 
 
There occurs a transmutation of elements: the daughter isotope has the same 
mass number but an atomic number reduced by one than the parent. This is ac-
companied by the emission of a neutrino, a particle with no mass or charge, and 
an highly interactive positron (small mass and positive charge). While the neutri-
no escapes without interacting in the surrounding material, the positron after 
travelling a short distance (3-5 mm) is showed down by the scattering processes 
in the electron clouds of the surrounding environment. The distance traveled by 
the positron is known as its range and is function of the PET isotopes and then of 
Isotope half-life  
(min) 
Maximum 
positron 
energy (MeV) 
Production  
method 
11C 20.3 0.96 cyclotron 
13N 9.97 1.19 cyclotron 
15O 2.03 1.70 cyclotron 
18F 109.8 0.64 cyclotron 
68Ga 67.8 1.89 generator 
82Rb 1.26 3.15 generator 
zX           z-1X* + e+ + υ 
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the positron energy (18F, 11C, 15O, and 82Rb in water or tissue have a range be-
tween 2.6 and 16.5 mm). 41    
As positrons travel through human tissues, there is a continuous loss in kinetic 
energy principally due to Coulomb interactions with electrons. When a positron 
reaches thermal energies, it combines with an electron either by annihilation, 
which produces two photons of 511 KeV each, or by the formation of a very 
short-lived particle called positronium (Figure 11).   
 
 
The positronium is unstable 
and susceptible to the pick-off 
process, where it annihilates 
with another electron. In both 
cases the emitted pair of pho-
tons have an energy equivalent 
to the combined rest mass of an electron and a positron, and they are emitted at 
about 180° from each other.   
The image acquisition is based on the detection of emitted -rays by the detec-
tors surrounding the subject, which register the arrival of the annihilation pho-
tons as an event if the two detections occur within a narrow timing window (typ-
ically 3-15 ns). This “coincidence detection”, termed electronic collimation, is a 
fundamental require-
ment of detection be-
cause is assumed that 
the annihilation of the 
same electron-
positron couple takes 
place somewhere on 
the straight line 
drawn between the 
two detectors, termed 
line of response (LOR) 
or coincidence line. 
 e+ + e-       +      
 
Figure 11. Positron emission and annihilation. 40    
Figure 12. Coincidence detection (author Jens Langner).   
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These coincidence events provide information about the quantity and location of 
positrons: they are recorded and used in the image reconstruction through stan-
dard topographic techniques (Figure 12).41     
 
F A C T O R S  L I M IT I N G  TH E  S P A T I A L  R E S O L U TIO N  O F  PET 4 1      
 
 Positron range. PET scanner does not provide information on the distribu-
tion of positron emission points, because it detects -rays emitted at the an-
nihilation point. Positron emission point and annihilation point generally are 
not coincident because, as referred earlier, positrons travel some distance 
(range) within the surrounding material before it combines with an electron 
and emits the annihilation photons.    
 Non-colinearity of the annihilation photons. Owing to some residual mo-
mentum of the positron before it combines with the electron, the annihilation 
photons are emitted at not exactly 180° from each other, resulting in a coin-
cidence line usually shifted of a angle smaller than 0.5° leading to blurring in 
the image. 
 Detector size. The intrinsic detector spatial resolution also influences the 
quality of the reconstructed image. In modern PET scanners, the detectors 
use small crystal arrays coupled to large photodetectors.          
 
PET  R A D I O N U C L I D E S   
 
The choice of the radionuclide to be used in a PET exam is influenced by differ-
ent considerations:36     
 availability of the radionuclide; 
 physical characteristics; 
 radiochemical issues; 
 radiopharmacological issues.   
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As reported earlier in Table 2, all widely used PET nuclides have a very short 
half-life with limited availability: this on the one hand ensures a low dose re-
leased to the patient, but on the other side limits the clinical applicability on a 
routine basis. Therefore the production of PET nuclides has to be performed in a 
medical cyclotron on-site. Only fluorine-18 and gallium-68 do not require a cyc-
lotron in PET sites. 36      
PET radionuclides are generally obtained from the cyclotron (or generator) in a 
chemical form that is not predisposed for direct labeling reactions and thus are 
required several primary activation steps. Activated radionuclides are subse-
quently incorporated into the chemical structure of the vehicle molecule. 36     
A fundamental parameter that influences the imaging output is the specific ra-
dioactivity of the PET tracer, because a low specific activity would lead to low or 
undetectable signals: in the other words, the lower the density of the target sites 
the higher the required specific activity. 41      
 
TSPO  RADIOLIGANDS  
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Figure 13. Chemical structures of various PET tracers for imaging of the TSPO.    
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1-(2-chlorophenyl-N-methyl-N-(1-methylpropil)-3-isoquinolinecarboxamide (PK 
11195, 5) labeled with the positron emitter carbon-11 (t1/2  20.4 min., β+  
99.8%) was the first TSPO radioligand to be used, first as racemate and later as 
R-enantiomer, in PET imaging of neurodegenerative pathologies, multiple scle-
rosis, brain tumors, cerebral infarct, and calcium channel anomalies in heart dis-
eases. However, this radioligand presents several limitations, especially for brain 
imaging, including a high plasma protein binding and a poor penetration of the 
blood-brain barrier, which results in low levels of tracer in the brain. In addition, 
the high lipophilicity (logP  3.4) of 11CPK 11195 (11) causes a high level of 
nonspecific binding and a poor signal-to-noise ratios that complicate its quantifi-
cation and reduce its sensitivity in the in vivo evaluation of TSPO. Nevertheless, 
11CPK 11195 (11) is still used as reference radioligand for the in vivo assess-
ment of TSPO in PET studies.38,42      
Subsequently, Matarrese et al.43 labeled new conformationally restrained quino-
line-2-carboxamide derivatives analogues of PK 11195 (5) as potential radioli-
gands to investigate TSPO in vivo. The radioligands were synthesized by 11C-
N-methylation from the corresponding desmethyl precursors. Among the com-
pounds assayed, radioligand N-11C-VC195 (12), demonstrating a highly specific 
binding and tissue-to-blood ratios, emerged of potential interest for in vivo PET 
monitoring of neurodegenerative processes, but at the same time the high back-
ground levels of the tracer in the brain reduce its sensitivity.42 
Even several phenoxyphenylacetamide derivatives, such as 11CDAA1106 (13), 
were radiolabeled with carbon-11 for PET imaging of TSPO. Zhang and co-
workers44 observed that these radioligands pass across the blood-brain barrier, 
enter the rat brain and preferably distribute in the olfactory bulb and cerebellum, 
where there is the richest TSPO density in the rat brain. The binding specificity 
to the TSPO in the rat brain was demonstrated through the co-injection of non-
radiolabeled TSPO-selective ligands resulting in a strong reduction of tracer up-
take in the both brain regions. 11CDAA1106 (13) has been reported to be able 
to detect activation of microglia in several rat models of inflammations. 
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11CDPA713 (14) is a pyrazolopyrimidine derivative proposed as a PET tracer 
for the TSPO because has a lower lipophilicity, and higher selectivity and affinity 
(Ki  4.7 nM) toward the TSPO than 11CPK 11195 (Ki  9.3 nM). This TSPO 
antagonist was evaluated in vivo in a healthy baboon and it was observed a high-
er signal-to-noise ratios than 11C-(R)-PK 11195 in a rat model of neurodegene-
ration, which makes 11CDPA713 suitable for quantification and studying of 
changes in the density of TSPO binding sites.45 
Another example of TSPO radioligand is 11Cvinpocetine (15), a Vinca minor 
alkaloid, that binds specifically the TSPO and used as a neuroprotective drug in 
the treatment and prevention of cerebrovascular diseases. 11Cvinpocetine has 
showed a cerebral uptake 5-fold higher than that of 11CPK 11195 and a an he-
terogeneous distribution in the brain of monkeys. It is mainly metabolized in 
11Cethanol, that is showed not significantly contribute to the brain radioactivi-
ty pattern of 11Cvinpocetine.42   
                  
N 1 - M E TH Y L -2- PH E N Y L I N D O L -3- Y L G L Y O X Y LA M I D E S  
 
N,N-dialkyl-(2-phenylindol-3-yl)glyoxylamides have been described as new po-
tent and selective TSPO ligands, and then suitable for the development of novel 
PET radioligands for TSPO. SAR data and previously reported pharmaco-
phore/topological model hypothesis (Figure 14) suggest that indole NH should 
not be involved in the recognition of the receptor protein.38 
N
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N1-methyl-2-phenylindol-3-ylglyoxylamides
 
Figure 14. TSPO pharmacophore/topological model. 
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In 2011 Pike et al. 
38 reported a novel series of 2-phenylindol-3-ylglyoxylamides 
featuring a methyl substituent on the indole nitrogen and showing a high affinity 
for TSPO, with Ki values comparable to those of N1-unsubstitued parent com-
pounds. The binding data of N1-methylated indoles 16-26, expressed as Ki values 
and determined in rat kidney membranes by binding competition experiments 
against 11CPK 11195 as radioligand, are listed in Table 3, and compared with 
those of the N1-unbsustitued parent compounds (Id, Ie, Ig, Ih, Ij, In, Ip, Iv, Isss, 
Ittt, Iuuu, Izzz, Iaab) and the standard TSPO ligands 2, 5, and 6. 
All these compounds show Ki values in the low nanomolar or subnanomolar 
range, from 0.3 to 0.60 nM, essentially comparable with those of their unsubsti-
tued counterparts, and these data validate the hypothesis that the insertion of the 
methyl group at the N1 position does not significantly influence TSPO binding. 
The compound 24 is the only exception, with the lowest K1 value (Ki  190 nM), 
while compounds 17 and 18 possess the highest affinity in the series (K1  0.30 
nM) with a gain in activity of 25 and 4.6 fold respect to the unmethylated coun-
terparts, Ie and Ig, respectively.38 
The high affinity of the compounds 16-26 made them suitable for the develop-
ment of radioligands for imaging brain TSPO with PET. The best candidate to 
be labeled at the N1 position with the positron emitter carbon-11, by treatment 
with 11Cmethyl iodide and solid KOH in DMSO, is the compound 23 which 
shows the best combination of affinity (Ki  5.7 nM), adequately high toward 
TSPO, and lipophilicity (cLogP  3.95), with a low nonspecific binding and a li-
pophilic/hydrophilic balance suitably moderate for crossing the blood-brain bar-
rier and achieving an adequate brain concentration.38   
11C23 was synthesized by Pike and coworkers and tested with PET in rhesus 
monkeys, revealing a high proportion of radioligand to brain TSPO in the base-
line experiments and furthermore the reversibility of this binding. Moreover, 
this radioligand was studied for the characteristics of its binding to brain mem-
branes collected from a cohort of human subjects. 
In conclusion, this research group has discovered a promising new chemotype 
for development of novel TSPO radioligands as biomarkers of neuroinflamma-
tion.    
introduction 41 
 
Table 3. TSPO binding affinity of N,N-dialkylindolylglyoxylamide derivatives 16-26 
compared to those of the unmethylated counterparts (Id, Ie, Ig, Ih, Ij, In, Ip, Iv, Isss, 
Ittt, Iuuu, Izzz, Iaab).   
 
 
 
 
n R1 R2 R3 R4 R5 R6 
Ki (nM) or inhibition (%)
c 
TSPOa CBRb 
Ro 5-4864      23.03.0  
PK 11195      9.300.5  
alpidem      0.5 – 7 1 – 28 
Id (CH2)2CH3 (CH2)2CH3 H H H H 12.21.0 16% 
16 (CH2)2CH3 (CH2)2CH3 H CH3 H H 19.51.5  
Ie (CH2)3CH3 (CH2)3CH3 H H H H 7.50.7 3% 
17 (CH2)3CH3 (CH2)3CH3 H CH3 H H 0.3000.05  
Ig (CH2)5CH3 (CH2)5CH3 H H H H 1.40.2 10% 
18 (CH2)5CH3 (CH2)5CH3 H CH3 H H 0.2990.05  
Ih CH(CH3)2 CH(CH3)2 H H H H 1039.0  
19 CH(CH3)2 CH(CH3)2 H CH3 H H 64.895.2  
Ij CH2CH3 CH2C6H5 H H H H 11.01.0  
20 CH2CH3 CH2C6H5 H CH3 H H 2.920.3  
In (CH2)2CH3 (CH2)2CH3 F H H H 4.280.32 4.3% 
21 (CH2)2CH3 (CH2)2CH3 F CH3 H H 19.802.0  
Ip (CH2)5CH3 (CH2)5CH3 F H H H 0.370.13 0% 
22 (CH2)5CH3 (CH2)5CH3 F CH3 H H 1.070.11  
Iv (CH2)2CH3 (CH2)2CH3 NO2 H H H 0.950.1  
23 (CH2)2CH3 (CH2)2CH3 NO2 CH3 H H 5.700.45  
Isss CH3 (CH2)3CH3 H H H H 53.34.0  
24 CH3 (CH2)3CH3 H CH3 H H 190.010  
Ittt CH3 (CH2)4CH3 H H H H 12.11.0  
25 CH3 (CH2)4CH3 H CH3 H H 38.164.0  
Iuuu CH2CH3 (CH2)3CH3 H H H H 12.61.0  
N
N R2
R1
O
R6
R4
R5
R3
O
I
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(table 3) contd… 
a The concentration of tested compounds that inhibited 3HPK 11195 binding to rat 
kidney mitochondrial membranes (IC50) by 50% was determined with six concentrations 
of the displacers, each performed in triplicate. Ki values are the mean  SEM of three de-
terminations. b The inhibition percent of 3Hflumazenil specific binding at 10 μM of 
the compound are the mean  SEM of five determinations. Ki values are the mean  
SEM of three determinations. c Data taken from ref. 38 
 
n R1 R2 R3 R4 R5 R6 
Ki (nM) or inhibition (%)
c 
TSPOa CBRb 
26 CH2CH3 (CH2)3CH3 H CH3 H H 60.246.0  
Izzz CH3 CH2C6H5 H H H H 12.01.0  
27 CH3 CH2C6H5 H CH3 H H 20.931.8  
Iaab CH3 CH2C6H5 F H H H 1.80.1  
28 CH3 CH2C6H5 F CH3 H H 6.770.5  
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INTRODUCTION TO EXPERIMENTAL SECTION 
 
N,N-dialkyl-2-phenylindol-3-ylglyoxylamide derivatives, designed in 2004 by 
Primofiore et al.35, have shown a high affinity for TSPO in the nanomolar to 
subnanomolar range and a high selectivity for TSPO. The same research group 
has successively refined the TSPO pharmacophore/topological model through 
the synthesis and the biological evaluation of a library of novel 2-phenylindol-3-
ylglyoxylamide derivatives of general formula (I).25  
 
N
N
R2
R1
O
R6
R4
R5
R3
O
L1
H1
L4
L3
N,N-dialkyl-2-phenylindol-3-ylglyoxylamides
I
 
As earlier mentioned, rationalizing the SARs in the light of the previously re-
ported pharmacophore/receptor model made up of three lipophilic pockets (L1, 
L3, L4) and an H-bond donor group (H1), these authors have individuated four 
fundamental interactions:4,38  
1. the second carbonyl group of the oxalyl bridge engages an H-bond with the 
donor site H1; 
2. the two lipophilic substituents R1 and R2 (linear or ramified alkyl, arylalkyl 
group) on the amide nitrogen interact hydrophobically with the L3 or L4 li-
pophilic pockets; 
3. the 2-phenyl group establishes -stacking interactions within the L1 pocket.     
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Taking into account these observations, the aim of this work is to refine the 
TSPO pharmacophore/topological model through the synthesis and biological 
evaluation of a series of N,N-dialkyl-2-phenylindol-3-ylglyoxylamides (II) bear-
ing a polar group at the 4’-position of the 2-phenyl ring (R3  NH2, OH, COOH), 
and of a series of N,N-dialkyl-2-(3-thienyl)indol-3-ylglyoxylamides (III). These 
compounds have been synthesized as symmetrical amides featuring linear alkyl 
chains of different length on the amide nitrogen (n-propyl, n-butyl, n-hexyl) to 
evaluate any changes in the interaction with the lipophilic pockets L3, L4 of the 
pharmacophore. The TSPO affinity of intermediary compounds featuring a 
OCH3 and a COOCH3 substituent in 4’-position has also been estimated.   
 
Figure 15. General structures of N,N-dialkyl-2-phenylindol-3-ylglyoxylamides (II) and 
N,N-dialkyl-2-(3-thienyl)indol-3-ylglyoxylamides (III). 
 
The basal expression of TSPO, as referred above in TSPO Distribution in Healthy 
and Pathological Tissue, is up-regulated in a number of neuropathologies, includ-
ing gliomas and neurodegenerative diseases, in various forms of brain injury and 
inflammation, as well as in a variety of tumors.  
Consequently, TSPO has been suggested as a promising diagnostic marker to 
image and measure the TSPO expression and distribution levels, and thus for 
evaluation of disease progression by means of specific fluorescent or radiolabeled 
ligands. In particular, PET imaging using TSPO ligands to label activated mi-
croglia offers quantitative measures of inflammation, and then can help to under-
stand the regional brain distribution, stage and severity of neuroinflammation. 
Evaluating a novel series of 2-phenylindol-3-ylglyoxylamides featuring a methyl 
substituent on the indole nitrogen the same research group, in collaboration with 
Pike and coworkers38, has observed that the insertion of the methyl group at 
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S
introduction to experimental section 45 
 
 
the N1-position does not significantly influence TSPO binding, according with 
the pharmacophore model proposed. Therefore, these authors have developed 
novel radioligands for imaging brain TSPO with PET labeling the indole at the 
N1-position with the positron emitter carbon-11, and have indicated these com-
pounds as promising new chemotype for development of novel TSPO radioli-
gands as biomarkers of neuroinflammation. 
Therefore, the choice to insert a polar group in the scaffold of indolylglyoxyla-
mide derivatives has been made with the purpose to improve the lipophil-
ic/hydrophilic balance, envisaging the possibility to develop novel TSPO radi-
oligands with a better pharmacokinetic profile. In fact, it has been previously ob-
served that highly lipophilic molecular probes show a high level of non-specific 
binding and thus a poor signal-to-noise ratios, a high plasma protein binding and 
thus a relatively poor penetration of the blood-brain barrier, which results in a 
low levels of tracer accumulation in brain.42 
At the same time, it has also been evaluated the influence on the TSPO binding 
of the insertion of the methyl group at the N1-position: N1-methylated indoles 
have been prepared and their Ki values compared with those of the N1-
unsubstitued parent compounds and the standard TSPO ligands Ro 5-4864 (2), 
PK11195 (5) and alpidem (6). 
In this thesis work it has been prepared and evaluated the compounds 49, 50 (2-
(3-thienyl)), 53, 54 (R3  NH2), 57, 58 (R3  OH), 62, 63, 64 (R3  COOH), me-
thylated at the N1-position, and the corresponding N1-unmethylated 47, 48 (2-
(3-thienyl)), 51, 52 (R3  NH2), 55, 56 (R3  OH), 59, 60, 61 (R3  COOH). It 
has also been estimated the Ki value of the intermediary N1-unmethylated com-
pounds 32, 33, 34 (R3  OMe), 35, 36, 37 (R3  COOMe), and of the correspond-
ing methylated 39, 40, 41(R3  OMe), 42, 43, 44 (R3  COOMe). 
The general synthetic procedures employed to prepare these compounds are 
shown in Scheme 1 and 2. They involve, as first step, the synthesis of the 2-
phenylindoles 29a-c and 2-(3-thienyl)indole 45 through a one-step Fischer in-
dole synthesis25 consisting in warming phenylhydrazine hydrochloride and the 
appropriate acetophenone, or methyl 4-acetylbenzoate, or acetylthiophene direct-
ly with an excess of acid catalyst PPA (polyphosphoric acid). The reaction mix-
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ture was then poured into ice and the precipitated solid was collected by filtra-
tion and purified by recrystallization from toluene.  
The indoles 29a-c and 45 were then acylated with oxalyl chloride in anhydrous 
ethyl ether at 0 °C to give the corresponding indolylglyoxylyl chlorides 30a-c 
and 46, which were allowed to react in dry toluene solution and nitrogen atmos-
phere with the appropriate amine in presence of triethylamine, in equimolar 
quantity so as neutralize the hydrochloridric acid formed during the reaction of 
condensation.35 The crude compounds, after washing with a solution of     
NaHCO3 dil. 5% and then with H2O to eliminate the amine not reacted, with HCl 
dil. 10% and again H2O to remove the excess of Et3N, were tritured at 0 °C with 
ethylic ether to yield the indolylglyoxylamides 1v, 31-37, and 47, 48 (more de-
tails on the chemical procedures have been reported in Experimental Section).  
These compounds were then methylated at the N1-position through the treat-
ment with sodium hydride and subsequent addition of an excess of methyl iodide 
in dry DMF.38 The reaction mixture was dripped into ice and the solid precipi-
tated was collected by filtration, dried and subsequently purified by recrystalliza-
tion from toluene to obtained the N1-methylated indolylglyoxylamides 23, 38-
44, and 49, 50. Their chemical-physical properties were determined, and their 
structures were confirmed by 1H-NMR data reported in Table 4 for compounds 
32-34, and 39-41 (R3  OMe), 35-37, and 42-44 (R3  COOMe), Table 5 for 
47-50 (2-(3-thienyl)), see Experimental Section for compounds 31 and 38 (R1  R2 
= (CH2)3CH3; R3  NO2), data of compounds 1v and 23 (R1  R2 = (CH2)2CH3; R3 
 NO2) are reported in literature
25. 
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n R3 
29a; 30a NO2 
29b; 30b  OCH3 
29c; 30c COOMe 
n R1R2 R3 
1v (CH2)2CH3 NO2 
31 (CH2)3CH3 NO2 
32 (CH2)2CH3 OMe 
33 (CH2)3CH3 OMe 
34 (CH2)5CH3 OMe 
35 (CH2)2CH3 COOMe 
36 (CH2)3CH3 COOMe 
37 (CH2)5CH3 COOMe 
23 (CH2)2CH3 NO2 
38 (CH2)3CH3 NO2 
39 (CH2)2CH3 OMe 
40 (CH2)3CH3 OMe 
41 (CH2)5CH3 OMe 
42 (CH2)2CH3 COOMe 
43 (CH2)3CH3 COOMe 
44 (CH2)5CH3 COOMe 
introduction to experimental section 48 
 
 
NH
NH2
+
PPA
120 oC
Scheme 2
ClCOCOCl
anh. Et2O
0 oC
anh. toluene
Et3N
r.t. 
NH
R2
R1
O
S
N
H
S
N
N R2
R1
O
H
O
S N
Cl
O
H
O
S
N
N R2
R1
O
O
S
CH3
1)NaH
2)CH3I
anh. DMF 
45
4647, 48
49, 50
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The synthesis of the target compounds 51-54 (R3  NH2), 55-58 (R3  OH), and 
59-64 (R3  COOH) was achieved by the procedures outlined in Schemes 3, 4 
and 5. Starting by the N1-methylated (23, 38-40, 42-44) and their parent unme-
thylated (1v, 31-33, 35-37 ) indoles, previously prepared, we obtain, through ap-
propriate reactions, the corresponding compounds featuring a polar group at the 
4’-position of the 2-phenyl ring.  
 
n R1R2 
47 (CH2)2CH3 
48 (CH2)3CH3 
49 (CH2)2CH3 
50 (CH2)3CH3 
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The Scheme 3, reported above, describes the general procedure for the synthesis 
of the 2-phenylindolylglyolamide derivatives bearing a NH2 in para position at 
the 2-phenyl ring:39 N,N-dialkyl-2-(4-nitrophenyl)indol-3-ylglyoxylamide de-
rivatives 1v, 31, and 23, 38 were catalytically hydrogenated over palladium to 
yield the relative amines 51, 52 and 53, 54 (see Experimental Section). Their 
chemical-physical properties and 1H-NMR data are reported in Table 6. 
 
 
 
n R1R2 R3 
51 (CH2)2CH3 NH2 
52 (CH2)3CH3 NH2 
53 (CH2)2CH3 NH2 
54 (CH2)3CH3 NH2 
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The indolylglyoxylamide derivatives featuring a OH group in R3 (55-58) were 
achieved through a demethylation of the methoxy group46 (Scheme 4) in para 
position of the 2-phenyl ring with BBr3, added dropwise in nitrogen atmosphere 
to a stirred suspension of N,N-dialkyl-2-(4-methoxyphenyl)indol-3-ylglyoxyl-
amide derivatives 32, 33 or 39, 40. Finally, methanol was added to the reaction 
mixture to hydrolyze the excess of BBr3, and crude compounds were recovered 
as a solid precipitated after evaporation under reduced pressure. Their chemical-
physical properties and 1H-NMR data are reported in Table 6. 
Instead, the Scheme 5 reported the synthetic procedure to obtain the com-
pounds 59-64 by hydrolysis of the methyl ester47 in para position adding li-
thium hydroxide monohydrate to a MeOH/H2O (3:1) solution of methyl 4-(3-
n R1R2 R3 
55 (CH2)2CH3 OH 
56 (CH2)3CH3 OH 
57 (CH2)2CH3 OH 
58 (CH2)3CH3 OH 
introduction to experimental section 51 
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dialkyl-aminoglyoxylylindol-2-yl)benzoate derivatives 35-37 or 42-44 (all de-
tails of the procedure are reported in Experimental section). Their chemical-
physical properties and 1H-NMR data are reported in Table 6.    
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n R1R2 R3 
59 (CH2)2CH3 COOH 
60 (CH2)3CH3 COOH 
61 (CH2)5CH3 COOH 
62 (CH2)2CH3 COOH 
63 (CH2)3CH3 COOH 
64 (CH2)5CH3 COOH 
  
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Table 4. Yields, melting points, and spectral data of compounds 32-34, 39-41 (R3  OMe) and 35-37, 42-44 (R3  COOMe). 
 
 
 
 
 
 
 
 
 
  
 
n R1  R2 R3 R4 yield (%) 
m.p. (°C) 
(crystallization  
solvent) 
1H-NMR 
(DMSO-d6, ppm) 
formula 
32 (CH2)2CH3 OCH3 H 52 
121-126  
(toluene) 
0.64-0.79 (m, 6H, CH2CH2CH3); 1.21-1.26 (m, 2H, 
CH2CH2CH3); 1.39-1.47 (m, 2H, CH2CH2CH3); 2.93-
3.06 (2t, 4H, J=7 Hz, CH2CH2CH3); 3.83 (s, 3H, OCH3); 
7.06 (d, 2H, J=8 Hz, ArH); 7.08-7.29 (m, 2H, ArH); 7.42 
(d, 1H, J=8 Hz, ArH); 7.50 (d, 2H, J=8 Hz, ArH); 8.01 
(d, 1H, J=8 Hz, ArH); 12.34 (s, 1H, NH exch. with 
D2O). 
C23H26N2O3 
33 (CH2)3CH3 OCH3 H 55 
117-121 
(toluene) 
0.68-0.85 (m, 6H, CH2CH2CH2CH3); 1.02-1.10 (m, 4H, 
CH2CH2CH2CH3); 1.13-1.41 (m, 4H, CH2CH2CH2CH3); 
2.99-3.03 (2t, 4H, J=7 Hz, CH2CH2CH2CH3); 3.83 (1s, 
3H, OCH3); 7.06 (d, 2H, J=8 Hz, ArH); 7.20-7.28 (m, 
2H, ArH); 7.46 (d, 1H, J=8 Hz, ArH); 7.53 (d, 2H, J=8 
Hz, ArH); 8.05 (d, 1H, J=8 Hz, ArH); 12.53 (s, 1H, NH 
exch. with D2O). 
C25H30N2O3 
34 (CH2)5CH3 OCH3 H 45 oil 
0.73-0.86 (2t, 6H, J=7 Hz, CH2CH2CH2CH2CH2CH3); 
1.04-1.21 (m, 12H, CH2CH2CH2CH2CH2CH3); 2.98-3.05 
(m, 4H, CH2CH2CH2CH2CH2CH3); 3.68-3.71 (m, 4H, 
CH2CH2CH2CH2CH2CH3); 3.83 (1s, 3H, OCH3); 7.05 (d, 
2H, J=7 Hz, ArH); 7.20-7.25 (m, 2H, ArH); 7.45 (d, 1H, 
J=6 Hz, ArH); 7.53 (d, 2H, J=7 Hz, ArH); 8.02 (d, 1H, 
J=6 Hz, ArH); 12.33 (s, 1H, NH exch. with D2O). 
C29H38N2O3 
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n R1  R2 R3 R4 yield (%) 
m.p. (°C) 
(crystallization  
solvent) 
1H-NMR 
(DMSO-d6, ppm) 
formula 
35 (CH2)2CH3 COOCH3 H 65 
139-141 
(toluene) 
0.66-0.77 (m, 6H, CH2CH2CH3); 1.20-1.27 (m, 2H, 
CH2CH2CH3); 1.45-1.49 (m, 2H, CH2CH2CH3); 2.93-
3.10 (2t, 4H, J=8 Hz, CH2CH2CH3); 3.92 (1s, 3H, 
COOCH3); 7.27-7.31 (m, 2H, ArH); 7.52 (d, 1H, J=8 Hz, 
ArH); 7.74 (d, 2H, J=8 Hz, ArH); 8.02-8.09 (m, 3H, 
ArH); 12.64 (s, 1H, NH exch. with D2O). 
C24H26N2O4 
36 (CH2)3CH3 COOCH3 H 61 
119-121 
(toluene) 
0.69-0.80 (m, 6H, CH2CH2CH2CH3); 1.00-1.15 (m, 4H, 
CH2CH2CH2 CH3); 1.25-1.41 (m, 4H, CH2CH2CH2CH3); 
2.95-3.09 (2t, 4H, J=7 Hz, CH2CH2CH2CH3); 3.89 (1s, 
3H, COOCH3); 7.25-7.30 (m, 2H, ArH); 7.49 (d, 1H, J=8 
Hz, ArH); 7.72 (d, 2H, J=8 Hz, ArH); 8.04-8.09 (m, 3H, 
ArH); 12.59 (s, 1H, NH exch. with D2O). 
C26H30N2O4 
37 (CH2)5CH3 COOCH3 H 55 oil 
0.66-0.77 (2t, 6H, J=7 Hz, CH2CH2CH2CH2CH2CH3); 
0.98-1.17 (m, 12H, CH2CH2CH2CH2CH2CH3); 1.32-1.46 
(m, 4H, CH2CH2CH2CH2CH2 CH3); 2.85-2.97 (m, 4H, 
CH2CH2CH2CH2CH2CH3); 3.81 (1s, 3H, COOCH3); 
7.18-7.21 (m, 2H, ArH); 7.40 (d, 1H, J=7 Hz, ArH); 7.64 
(d, 2H, J=8 Hz, ArH); 7.96-8.00 (m, 3H, ArH); 12.53 (s, 
1H, NH exch. with D2O). 
C30H38N2O4 
39 (CH2)2CH3 OCH3 CH3 69 
135-137 
(toluene) 
0.67-0.75 (m, 6H, CH2CH2CH3); 1.03-1.14 (m, 2H, 
CH2CH2CH3); 1.41-1.52 (m, 2H, CH2CH2CH3); 2.71-
2.97 (2t, 4H, J=7 Hz, CH2CH2CH3); 3.50 (s, 3H, NCH3); 
3.84 (s, 3H, OCH3); 7.07 (d, 2H, J=8 Hz, ArH); 7.32-
7.39 (m, 4H, ArH); 7.63 (d, 1H, J=8 Hz, ArH); 8.21 (d, 
1H, J=8 Hz, ArH). 
C24H28N2O3 
40 (CH2)3CH3 OCH3 CH3 57 oil 
0.70-0.82 (m, 6H, CH2CH2CH2CH3); 1.00-1.14 (m, 4H, 
CH2CH2CH2CH3); 1.20-1.41 (m, 4H, CH2CH2CH2CH3); 
2.82 (2t, 4H, J=8 Hz, CH2CH2CH2CH3); 3.31 (s, 3H, 
NCH3); 3.81 (1s, 3H, OCH3); 7.04 (d, 2H, J=8 Hz, ArH); 
7.27-7.36 (m, 4H, ArH); 7.60 (d, 1H, J=8 Hz, ArH); 8.19 
(d, 2H, J=8 Hz, ArH). 
C26H32N2O3 
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n R1  R2 R3 R4 yield (%) 
m.p. (°C) 
(crystallization  
solvent) 
1H-NMR 
(DMSO-d6, ppm) 
formula 
41 (CH2)5CH3 OCH3 CH3 63 oil 
0.71-0.87 (2t, 6H, J=7 Hz,CH2CH2CH2CH2CH2CH3); 
0.99-1.39 (m, 12H, CH2CH2CH2CH2CH2CH3); 2.70-2.86 
(m, 8H, CH2CH2CH2CH2CH2CH3); 3.45 (1s, 3H, NCH3); 
3.80 (1s, 3H, OCH3); 7.03 (d, 2H, J=8 Hz, ArH); 7.30-
7.35 (m, 3H, ArH); 7.59 (d, 1H, J=7 Hz, ArH); 7.92 (s, 
1H, ArH); 8.18 (d, 1H, J=7 Hz, ArH). 
C30H40N2O3 
42 (CH2)2CH3 COOCH3 CH3 56 
135-137 
(toluene) 
0.64-0.75 (m, 6H, CH2CH2CH3); 1.03-1.07 (m, 2H, 
CH2CH2CH3); 1.37-1.60 (m, 2H, CH2CH2CH3); 2.73-
2.98 (2t, 4H, J=8 Hz, CH2CH2CH3); 3.52 (s, 3H, NCH3); 
3.92 (s, 3H, COOCH3); 7.25-7.42 (m, 2H, ArH); 7.61-
7.65 (m, 3H, ArH); 8.06-8.20 (m, 3H, ArH). 
C25H28N2O4 
43 (CH2)3CH3 COOCH3 CH3 70 
105-108 
(toluene) 
0.55-0.79 (m, 6H, CH2CH2CH2CH3); 1.01-1.15 (m, 4H, 
CH2CH2CH2CH3); 1.17-1.41 (m, 4H, CH2CH2CH2CH3); 
2.82 (2t, 4H, J=7 Hz, CH2CH2CH2CH3); 3.46 (s, 3H, 
NCH3); 3.86 (1s, 3H. COOCH3); 7.27-7.34 (m, 2H, 
ArH); 7.56-7.61 (m, 3H, ArH); 8.04 (d, 2H, J=8 Hz, 
ArH); 8.18 (d, 1H, J=7 Hz, ArH). 
C27H32N2O4 
44 (CH2)5CH3 COOCH3 CH3 65 oil 
0.72-0.85 (2t, 6H, J=7 Hz, CH2CH2CH2CH2CH2CH3); 
1.00-1.12 (m, 12H, CH2CH2CH2CH2CH2CH3); 1.25-1.39 
(m, 4H, CH2CH2CH2CH2CH2CH3); 2.70-2.95 (m, 4H, 
CH2CH2CH2CH2CH2CH3); 3.46 (s, 3H, NCH3); 3.88 (1s, 
3H. COOCH3); 7.30-7.37 (m, 2H, ArH); 7.59 (d, 2H, J=8 
Hz, ArH); 7.65 (d, 1H, J=7 Hz, ArH); 8.05 (d, 2H, J=8 
Hz, ArH); 8.18 (d, 1H, J=7 Hz, ArH). 
C31H40N2O4 
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n R1  R2 R4 yield (%) m.p. (°C) 
1H-NMR 
(DMSO-d6, ppm) 
formula 
47 (CH2)2CH3 H 78 68-71 
0.65 (t, 3H, J=8 Hz, CH2CH2CH3); 0.81 (t, 3H, J=8 Hz, 
CH2CH2CH3); 1.30-1.50 (m, 4H, CH2CH2CH3); 3.00-3.14 
(m, 4H, CH2CH2CH3); 7.21-7.27 (m, 2H, ArH); 7.46-7.50 
(m, 2H, ArH); 7.69-7.73 (m, 1H, ArH); 7.91 (d, 1H, J=7 Hz, 
ArH); 8.13 (d, 1H, J=2 Hz, ArH); 12.45 (s, 1H, NH exch. 
with D2O). 
C20H22N2O2S 
48 (CH2)3CH3 H 79 118-121 
0.66 (t, 3H, J=7 Hz, CH2CH2CH2CH3); 0.89 (t, 3H, J=7 Hz, 
CH2CH2CH2CH3); 0.98.-1.09 (m, 4H, CH2CH2CH2CH3); 
1.21-1.36 (m, 4H, CH2CH2CH2CH3); 3.00-3.19 (2t, 4H, J=8 
Hz, CH2CH2CH2CH3); 7.16-7.30 (m, 2H, ArH); 7.45-7.49 
(m, 2H, ArH); 7.68-7.72 (m, 1H, ArH); 7.90 (d, 1H, J=8 Hz, 
ArH); 8.11 (s, 1H, ArH); 12.43 (s, 1H, NH exch. with D2O). 
C22H26N2O2S 
49 (CH2)2CH3 CH3 65 118-121 
0.67-0.81 (m, 6H, CH2CH2CH3); 1.24-1.48 (m, 4H, 
CH2CH2CH3); 2.80-3.00 (2t, 4H, J=8 Hz, CH2CH2CH3); 
3.54 (s, 3H, NCH3); 7.24 (d, 1H, J=7 Hz, ArH); 7.32-7.38 
(m, 2H, ArH); 7.65 (d, 1H, J=7 Hz, ArH); 7.72-7.79 (m, 2H, 
ArH); 8.21 (d, 1H, J=7 Hz, ArH). 
C21H24N2O2S 
50 (CH2)3CH3 CH3 67 104-107 
0.73-0.84 (m, 6H, CH2CH2CH2CH3); 1.03.-1.15 (m, 4H, 
CH2CH2CH2CH3); 1.17-1.40 (m, 4H, CH2CH2CH2CH3); 
2.85-2.97 (2t, 4H, J=8 Hz, CH2CH2CH2CH3); 3.51 (s, 3H, 
NCH3); 7.20-7.31 (m, 3H, ArH); 7.61 (d, 1H, J=7 Hz, 
ArH); 7.69-7.76 (m, 2H, ArH); 8.17 (d, 1H, J=7 Hz, ArH). 
C23H28N2O2S 
N
N R2
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O
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S
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Table 6. Yields, melting points, and spectral data of compounds 51-64 (R3  NH2; OH; COOH). 
  
 
 
 
 
n R1  R2 R3 R4 yield (%) 
m.p. (°C) 
(crystallization  
solvent) 
1H-NMR 
(DMSO-d6, ppm) 
formula 
51 (CH2)2CH3 NH2 H 52 
197-198 
(toluene) 
0.63-0.84 (m, 6H, CH2CH2CH3); 1.29-1.37 (m, 2H, 
CH2CH2CH3); 1.41-1.49 (m, 2H, CH2CH2CH3); 2.97-
3.08 (2t, 4H, J=7 Hz, CH2CH2CH3); 5.57 (s, 2H, NH2 
exch. with D2O); 6.62 (d, 2H, J=8 Hz, ArH); 7.17-7.43 
(m, 5H, ArH); 7.92-7.97 (m, 1H, ArH); 12.09 (s, 1H, NH 
exch. with D2O). 
C22H25N3O2 
52 (CH2)3CH3 NH2 H 61 
224-227 
(toluene) 
0.64-0.89 (m, 6H, CH2CH2CH2CH3); 0.98-1.00 (m, 4H, 
CH2CH2CH2CH3); 1.20-1.36 (m, 4H, CH2CH2CH2CH3); 
3.00-3.06 (2t, 4H, J=7 Hz, CH2CH2CH2CH3); 5.52 (s, 
2H, NH2 exch. with D2O); 6.61 (d, 2H, J=8 Hz, ArH); 
7.15-7.21 (m, 2H, ArH); 7.28 (d, 2H, J=8 Hz, ArH); 7.39 
(d, 1H, J=7 Hz, ArH); 7.94 (d, 1H, J=7 Hz, ArH); 12.08 
(s, 1H, NH exch. with D2O). 
C24H29N3O2 
53 (CH2)2CH3 NH2 CH3 82 
178-180 
(toluene) 
0.67-0.77 (m, 6H, CH2CH2CH3); 1.12-1.23 (m, 2H, 
CH2CH2CH3); 1.40-1.51 (m, 2H, CH2CH2CH3); 2.72-
2.97 (2t, 4H, J=8 Hz, CH2CH2CH3); 3.51 (s, 3H, NCH3); 
7.16-7.33 (m, 6H, ArH); 7.59 (d, 1H, J=8 Hz, ArH); 8.19 
(d, 1H, J=8 Hz, ArH); 8.56 (d, 2H, J=20 Hz, NH2 exch. 
with D2O); 
C23H27N3O2 
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n R1  R2 R3 R4 yield (%) 
m.p. (°C) 
(crystallization  
solvent) 
1H-NMR 
(DMSO-d6, ppm) 
formula 
54 (CH2)3CH3 NH2 CH3 79 
226-229 
(toluene) 
0.51-0.79 (m, 6H, CH2CH2CH2CH3); 1.00-1.15 (m, 4H, 
CH2CH2CH2CH3); 1.25-1.34 (m, 4H, CH2CH2CH2CH3); 
2.58-3.00 (2t, 4H, J=7 Hz, CH2CH2CH2CH3); 3.42 (s, 
3H, NCH3); 5.52 (s, 2H, NH2 exch. with D2O); 6.56 (d, 
2H, J=7 Hz, ArH); 6.97 (d, 2H, J=7 Hz, ArH); 7.19-7.29 
(m, 2H, ArH); 7.50 (d, 1H, J=7 Hz, ArH); 8.11 (d, 1H, 
J=7 Hz, ArH); 
C25H31N3O2 
55 (CH2)2CH3 OH H 59 
210-212 
(toluene) 
0.64-0.82 (m, 6H, CH2CH2CH3); 1.27-1.46 (m, 4H, 
CH2CH2CH3); 2.95-3.02 (2t, 4H, J=8 Hz, CH2CH2CH3); 
6.86 (d, 2H, J=8 Hz, ArH); 7.17-7.25 (m, 2H, ArH); 7.40 
(d, 3H, J=8 Hz, ArH); 8.01 (d, 1H, J=7 Hz, ArH); 9.89 
(s, 1H, OH exch. with D2O); 12.27 (s, 1H, NH exch. 
with D2O). 
C22H24N2O3 
56 (CH2)3CH3 OH H 68 249-252 
0.68-0.84 (m, 6H, CH2CH2CH2CH3); 1.02-1.14 (m, 4H, 
CH2CH2CH2CH3); 1.21-1.36 (m, 4H, CH2CH2CH2CH3); 
2.94-2.98 (2t, 4H, J=7 Hz, CH2CH2CH2CH3); 6.83 (d, 
2H, J=7 Hz, ArH); 7.19-7.21(m, 2H, ArH); 7.37-7.40 
(m, 3H, ArH); 7.98 (d, 1H, J=7 Hz, ArH); 9.84 (s, 1H, 
OH exch. with D2O); 12.22 (s, 1H, NH exch. with D2O). 
C24H28N2O3 
57 (CH2)2CH3 OH CH3 80 
248-250 
(toluene) 
0.67-0.77 (m, 6H, CH2CH2CH3); 1.09-1.21 (m, 2H, 
CH2CH2CH3); 1.41-1.52 (m, 2H, CH2CH2CH3); 2.72-
2.96 (2t, 4H, J=8 Hz, CH2CH2CH3); 3.50 (s, 3H, NCH3); 
6.88 (d, 2H, J=8 Hz, ArH); 7.23 (d, 2H, J=8 Hz, ArH); 
7.33-7.36 (m, 2H, ArH); 7.62 (d, 1H, J=8 Hz, ArH); 8.21 
(d, 1H, J=8 Hz, ArH); 9.88 (s, 1H, OH exch. with D2O). 
C23H26N2O3 
58 (CH2)3CH3 OH CH3 75 211-214 
0.70-0.83 (m, 6H, CH2CH2CH2CH3); 0.98-1.17 (m, 4H, 
CH2CH2CH2CH3); 1.20-1.40 (m, 4H, CH2CH2CH2CH3); 
2.76-2.92 (2t, 4H, J=7 Hz, CH2CH2CH2CH3); 3.46 (s, 
3H, NCH3); 6.83 (d, 2H, J=7 Hz, ArH); 7.19 (d, 2H, J=7 
Hz, ArH); 7.23-7.31 (m, 2H, ArH); 7.58 (d, 1H, J=7 Hz, 
ArH); 8.18 (d, 1H, J=7 Hz, ArH); 9.85 (s, 1H, OH exch. 
with D2O). 
C25H30N2O3 
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63 (CH2)3CH3 COOH CH3 70 148-151 
0.74-0.91 (m, 6H, CH2CH2CH2CH3); 1.02-1.18 (m, 4H, 
CH2CH2CH2CH3); 1.24-1.45 (m, 4H, CH2CH2CH2CH3); 
2.73-3.03 (2t, 4H, J=7 Hz, CH2CH2CH2CH3); 3.51 (s, 
3H, NCH3); 7.31-7.44 (m, 2H, ArH); 7.59 (d, 2H, J=8 
Hz, ArH); 7.68 (d, 1H, J=8 Hz, ArH); 8.06 (d, 2H, J=8 
Hz, ArH); 8.24 (d, 1H, J=8 Hz, ArH). 
C26H30N2O4 
n R1  R2 R3 R4 yield (%) 
m.p. (°C) 
(crystallization  
solvent) 
1H-NMR 
(DMSO-d6, ppm) 
formula 
59 (CH2)2CH3 COOH H 85 292-294 
0.64-0.75 (m, 6H, CH2CH2CH3); 1.15-1.26 (m, 2H, 
CH2CH2CH3); 1.43-1.47 (m, 2H, CH2CH2CH3); 2.88-
3.15 (2t, 4H, J=8 Hz, CH2CH2CH3); 7.27-7.31 (m, 2H, 
ArH); 7.51 (d, 1H, J=8 Hz, ArH); 7.71 (d, 2H, J=8 Hz, 
ArH); 8.04 (d, 3H, J=8 Hz, ArH); 12.63 (s, 1H, NH 
exch. with D2O). 
C23H24N2O4 
60 (CH2)3CH3 COOH H 87 147-150 
0.68-0.80 (m, 6H, CH2CH2CH2CH3); 1.03-1.08 (m, 4H, 
CH2CH2CH2CH3); 1.10-1.40 (m, 4H, CH2CH2CH2CH3); 
2.93-3.04 (2t, 4H, J=7 Hz, CH2CH2CH2CH3); 7.25-7.28 
(m, 2H, ArH); 7.48 (d, 1H, J=7 Hz, ArH); 7.68 (d, 2H, 
J=7 Hz, ArH); 8.00-8.07 (m, 3H, ArH); 12.56 (s, 1H, 
NH exch. with D2O). 
C25H28N2O4 
61 (CH2)5CH3 COOH H 79 241-244 
0.73-0.84 (2t, 6H, J=7 Hz, CH2CH2CH2CH2CH2CH3); 
1.00-1.12 (m, 12H, CH2CH2CH2CH2CH2CH3); 1.27-1.39 
(m, 4H, CH2CH2CH2CH2CH2CH3); 2.93-3.03 (m, 4H, 
CH2CH2CH2CH2CH2CH3); 7.24-7.27 (m, 2H, ArH); 7.48 
(d, 1H, J=7 Hz, ArH); 7.68 (d, 2H, J=8 Hz, ArH); 8.00-
8.05 (m, 3H, ArH); 12.56 (s, 1H, NH exch. with D2O). 
C29H36N2O4 
62 (CH2)2CH3 COOH CH3 68 287-290 
0.68-0.72 (m, 6H, CH2CH2CH3); 0.95-1.20 (m, 2H, 
CH2CH2CH3); 1.37-1.61 (m, 2H, CH2CH2CH3); 2.70-
3.11 (2t, 4H, J=8 Hz, CH2CH2CH3); 3.37 (s, 3H, NCH3); 
7.28-7.45 (m, 2H, ArH); 7.61 (d, 2H, J=8 Hz, ArH); 7.72 
(d, 1H, J=8 Hz, ArH); 8.08 (d, 2H, J=8 Hz, ArH); 8.20 
(d, 1H, J=8 Hz, ArH). 
C24H26N2O4 
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n R1  R2 R3 R4 yield (%) 
m.p. (°C) 
(crystallization  
solvent) 
1H-NMR 
(DMSO-d6, ppm) 
formula 
64 (CH2)5CH3 COOH CH3 73 194-196 
0.73-0.87 (2t, 6H, J=7 Hz, CH2CH2CH2CH2CH2CH3); 
1.11-1.22 (m, 12H, CH2CH2CH2CH2CH2CH3); 1.37-1.42 
(m, 4H, CH2CH2CH2CH2CH2CH3); 2.74-3.00 (2t, 4H, 
J=7 Hz, CH2CH2CH2CH2CH2CH3); 3.49 (s, 3H, NCH3); 
7.32-7.39 (m, 2H, ArH); 7.57 (d, 2H, J=8 Hz, ArH); 7.66 
(d, 1H, J=8 Hz, ArH); 8.05 (d, 2H, J=8 Hz, ArH); 8.21 
(d, 1H, J=8 Hz, ArH). 
C30H38N2O4 
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BIOLOGICAL STUDIES 
 
All products synthesized during this thesis work were assayed by the research 
group of Prof. Claudia Martini, Dipartimento di Psichiatria, Neurobiologia, 
Farmacologia e Biotecnologie, University of Pisa.  
The binding affinity at TSPO of all the newly synthesized compounds 47-64 was 
determined in rat kidney membranes by binding competitions experiments 
against 3HPK 11195 as radioligand.35 For binding studies, crude mitochondri-
al membranes were incubated with 3HPK 11195 (o.6 nM) in the presence of the 
test compound in the concentration range (0.05 nM-10 μM) in Tris-HCl buffer 
(50 mM, pH 7.4), as described in literature. 35 For the active compounds, the 
IC50 values were determined and Ki values were derived according to the Cheng-
Prusoff equation. 48  
Table 7 reports the TSPO binding affinity data expressed as Ki values (nM), of a 
number of compounds synthesized in this thesis work (not all were available yet), 
together with the Ki values of the standard Ro 5-4864 (2), PK11195 (5), and al-
pidem (6), and of the reference compounds 1d and 16.  
It should be noted that all compounds show good to high affinity for TSPO, with 
Ki values in the nanomolar range.   
Analysis of these preliminary data allowed to make few main considerations: 
1) The insertion of a methoxy group at the 4’-position of Id yields compound 32 
showing a slight increase in TSPO affinity (Id Ki = 12.2 nm, 32 Ki= 5.82 
nM) 
2) The insertion of hydrophilic substituents (OH, NH2, COOH) on the 2-phenyl 
ring (compounds 52, 55, and 59) does not determine any significant im-
provement of the affinity, suggesting the interaction at the level of the L1 
pocket is mostly lipophilic.  
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In particular, the insertion of a OH group at the 4-position of the 2-phenyl 
ring is tolerated for TSPO affinity (Id, Ki = 12.2 nm, 55 Ki = 16.13 nM). 
Conversely, a decrease of the binding affinity is observed introducing a NH2 
or, to a major extent, a COOH group (Id, Ki = 12.2 nm, 51 Ki = 44.4 nM, 59 
343).      
3) Insertion of a methyl group on the indole N1 nitrogen produces different ef-
fects on TSPO affinity in dependence of the substituent at 4’-position. From 
the pair-wise comparison of the N1-methyl derivatives with their correspond-
ing N1-H counterparts, the following observations could be drawn: 
 the affinity is substantially maintained when the 2-phenyl ring is un-
substituted (Id, Ki = 12.2 nm, 16 Ki = 19.5 nM) or features a 4’-
methoxy group (32, Ki = 5.82 nm, 39 Ki = 14.65 nM)  
 a significant improvement in TSPO affinity was observed when a 
NH2 group is present at 4’-position (51, Ki = 44.4 nm, 53 Ki = 5.63 
nM), and 53 resulted the most potent compound among the products 
tested. 
 the contemporary presence of N1-methyl and 4’-OH moieties yields a 
detrimental effect on TSPO affinity (55, Ki = 16.13 nm, 57 Ki = 143.3 
nM). 
Summarizing, it should be speculated that the substitutions at 1- and 4’-positions 
seem to significantly modulate TSPO affinity in an interdependent and not addi-
tive way.  
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N
N R2
R1
O
R4
R3
O
Table 7. Preliminary data of the receptor binding affinity for TSPO. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a The concentration of tested compounds that inhibited 3HPK 11195 binding to rat 
kidney mitochondrial membranes (IC50) by 50% was determined with six concentrations 
of the displacers, each performed in triplicate. Ki values are the mean  SEM of three de-
terminations. 
 
 
n R1  R2 R3 R4 
TSPO 
Ki (nM)
a 
Id 
 
(CH2)2CH3 H H 12.2±1.0 
16 
 
(CH2)2CH3 H CH3 19.5±1.5 
32 
 
(CH2)2CH3 OCH3 H 5.82±0.5 
39 
 
(CH2)2CH3 OCH3 CH3 14.65±1.5 
51 
 
(CH2)2CH3 NH2 H 44.45.0 
53 
 
(CH2)2CH3 NH2 CH3 5.63±0.6 
55 
 
(CH2)2CH3 OH H 16.13±1.0 
57 
 
(CH2)2CH3 OH CH3 143.3±15 
59 
 
(CH2)2CH3 COOH H 343.0±10 
Ro 5-4864 
 
 
 
 23.03.0 
PK 11195 
 
 
 
 9.300.5 
alpidem 
 
 
 
 0.5 – 7 
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EXPERIMENTAL SECTION 
 
MATERIALS AND METHODS  
 
Melting points were determined using a Reichert Köfler hot-stage apparatus and 
are uncorrected. Infrared spectra were recorded with a Nicolet/Avatar FT-IR 
spectrometer in Nujol mulls. Routine nuclear magnetic resonance spectra were 
recorded in DMSO-d6 solution on a Varian Gemini 200 spectrometer operating 
at 200 MHz. Evaporation was performed in vacuo (rotary evaporator). Analytical 
TLC was carried out on Merck 0.2 mm precoated silica gel aluminum sheets (60 
F-254). Silica gel 60 Merck (230-400 mesh ASTM) was used for column chroma-
tography. Anhydrous reactions were performed in flame-dried glassware under 
N2. All compounds showed  95% purity. 
All reagents used were obtained from commercial sources. All solvents were of 
an analytical grade.    
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CHEMISTRY  
 
 
General procedure for the synthesis of:  
2-phenyl-1H-indole derivatives (29a, 29b) 
methyl 4-(1H-indol-2-yl)benzoate derivative (29c) 
2-(3-thienyl)-1H-indole derivative (45) 
1 g of polyphosphoric acid (PPA) was added to a mixture of phenylhydrazine 
chlorhydrate (5.0 mmol) and methyl 4-acetylbenzoate (5.0 mmol), or the appro-
priate acetophenone (5.0 mmol), or acetylthiophene (5.0 mmol). The reaction was 
maintained at 75°C for 30 min for 29a (TLC analysis: petroleum ether/ethyl ace-
tate, 7:3), at 120°C for 4 h for 29b (TLC analysis: toluene/acetonitrile, 9:1) and 
45 (TLC analysis: chloroform), and at 60°C for 4 h for compound 29c (TLC 
analysis: chloroform). When the starting material was disappeared, the reaction 
mixture was poured into ice and the precipitated solid was collected by filtration. 
All products were purified by recrystallization from toluene. 
Yield, melting point, and spectral data of compound 29a were reported in litera-
ture.25    
 
2-(4-methoxyphenyl)-1H-indole (29b). Yield: 84%; m. p.: 231-234 °C; 1H-NMR 
(DMSO-d6, ppm): 3.80 (s, 3H, OCH3); 6.76 (d, 1H, J  1.8 Hz, ArH); 6.96-7.09 (m, 
4H, ArH); 7.36 (d, 1H, J  8 Hz, ArH); 7.49 (d, 1H, J  7.2 Hz, ArH); 7.77-7.81 
(m, 2H, ArH); 11.40 (s, 1H, NH exch. with D2O). 
Methyl 4-(1H-indol-2-yl)benzoate (29c). Yield: 78%; m. p.: 204-207 °C; 1H-NMR 
(DMSO-d6, ppm): 3.87 (s, 3H, COOCH3); 7.02-7.15 (m, 3H, ArH); 7.43 (d, 1H, 
J=8 Hz, ArH); 7.57 (d, 1H, J=8 Hz, ArH); 8.02 (s, 4H, ArH); 11.73 (s, 1H, NH 
exch. with D2O). 
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2-(3-thienyl)-1H-indole (45). Yield: 89%; m. p.: 243-245 °C; 1H-NMR (DMSO-d6, 
ppm): 6.76 (d, 1H, J  0.8 Hz, ArH); 6.94-7.12 (m, 2H, ArH); 7.37 (d, 1H, J  8 
Hz, ArH); 7.51 (d, 1H, J  8 Hz, ArH); 7.59-7.67 (m, 2H, ArH); 7.87 (t, 1H, J  
1.5 Hz, ArH).  
 
 
General procedure for the synthesis of:  
(2-phenylindol-3-yl)glyoxylyl chloride derivatives (30a, 30b) 
methyl 4-(3-chloroglyoxylylindol-2-yl)benzoate derivative (30c) 
2-(3-thienyl)indol-3-ylglyoxylyl chloride derivative (46) 
Oxalyl chloride (8.0 mmol) was added dropwise at 0°C to a well-stirred mixture 
of the appropriate indole 29a-c or 45 (4.0 mmol) in freshly distilled diethyl ether 
(10 mL). The mixture was maintained at room temperature for 2-24 h (TLC 
analysis: chloroform). A solid precipitate was obtained in the case of compounds 
30b and 30c, which was collected by vacuum filtration, and immediately used in 
the subsequent reaction. Instead, starting by compounds 29a and 45, it was not 
observed any formation of precipitate: thus, the solvent of reaction was evapo-
rated under reduced pressure, and the generated solid was washed with portions 
of anhydrous diethyl ether to give the correspondent acyl chlorides 30a and 46. 
 
2-(4-nitrophenyl)indol-3-ylglyoxylyl chloride (30a). Yield: 60% 
2-(4-methoxyphenyl)indol-3-ylglyoxylyl chloride (30b). Yield: 72% 
Methyl 4-(3-chloroglyoxylylindol-2-yl)benzoate (30c). Yield: 80% 
2-(3-thienyl)indol-3-ylglyoxylyl chloride (46). Yield: 65% 
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General procedure for the synthesis of: 
N,N-dialkyl-(2-phenylindol-3-yl)glyoxylamide derivatives (1v, 31-34) 
methyl 4-(3-dialkylaminoglyoxylylindole-2-yl)benzoate derivatives (35-37) 
N,N-dialkyl-2-(3-thienyl)indol-3-ylglyoxylamide derivatives (47, 48) 
A solution of an appropriate ammine (2.0 mmol) in 5 mL of dry toluene was add-
ed dropwise to a stirred suspension, cooled at 0°C, of the (2-phenylindol-3-
yl)glyoxylyl chloride derivatives 30a-30b (2.0 mmol), or methyl 4-(3-
chloroglyoxylylindol-2-yl)benzoate derivative 30c (2.0 mmol), or 2-(3-thienyl)indol-
3-ylglyoxylyl chloride derivative 46 (2.0 mmol) in 50 mL of the same solvent, fol-
lowed by the addition of a solution of triethylamine (2.0 mmol). The reaction 
mixture was left under stirring for 2-24 h at room temperature (TLC analysis 
with appropriate eluent), and then filtered. The collected precipitate was tritu-
rated with a NaHCO3 5% aqueous solution, washed with water, and collected 
again to give a first portion of crude product. The toluene solution was instead 
removed under reduced pressure, and the oily residue obtained was extracted 
with CHCl3 and purified by washing with 1) a solution of NaHCO3 dil. 5%; 2) 
H2O; 3) HCl dil. 10%; and finally 4) H2O. After drying with MgSO4, the chloro-
form solution was evaporated to dryness, and the residue was tritured at 0 °C 
with ethylic ether to yield the crude product, that was collected by filtration. In 
the case of less soluble products, the crude compound precipitates together with 
the triethylamine hydrochloride and was collected, after washing with a solution 
of NaHCO3 dil. 5%, and dried over P2O5 in vacuo. 
All products generally did not require additional purification steps, but in the 
case of dirty compounds they were purified by recrystallization from toluene; on-
ly the compound 1v, N,N-di-n-propyl-2-(4-nitrophenyl)indol-3-ylglyoxylamide, 
was purified by flash chromatography (CHCl3 as eluent), as reported in litera-
ture.25    
Yields, melting points, and spectral data of compounds 32-37 are listed in Table 
4, 47 and 48 in Table 5, while those of compound 1v were reported in litera-
ture.25    
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N,N-di-n-butyl-2-(4-nitrophenyl)indol-3-ylglyoxylamide (31). Yield: 57%; m. p.: 
201-203 °C; 1H-NMR (DMSO-d6, ppm): 0.70-0.78 (m, 6H, CH2CH2CH2CH3); 
0.97-1.20 (m, 4H, CH2CH2CH2CH3); 1.32-1.53 (m, 4H, CH2CH2CH2CH3); 3.07 
(2t, 4H, J=8 Hz, CH2CH2CH2CH3); 7.22-7.37 (m, 2H, ArH); 7.54 (d, 1H, J=7 Hz, 
ArH); 7.89 (d, 2H, J=8 Hz, ArH); 8.05 (d, 1H, J=7 Hz, ArH); 8.38 (d, 2H, J=8 Hz, 
ArH); 12.74 (s, 1H, NH exch. with D2O).      
 
 
General procedure for the synthesis of: 
N,N-dialkyl-(N1-methyl-2-phenylindol-3-yl)glyoxylamide derivatives (23, 38-41) 
methyl 4-(N1-methyl-3-dialkylaminoglyoxylylindol-2-yl)benzoate derivatives (42-44) 
N,N-dialkyl-2-N1-methyl-(3-thienyl)indol-3-ylglyoxylamide derivatives (49, 50) 
Sodium hydride (0.2 mmol, 60 % dispersion in mineral oil) was added portionwi-
se, under a nitrogen atmosphere, to an ice-coooled solution of the appropriate 
N,N-dialkyl-(2-phenylindol-3-yl)glyoxylamide derivatives 1v, 31-34 (0.2 mmol), or 
methyl 4-(3-dialkylaminoglyoxylylindole-2-yl)benzoate derivatives 35-37 (0.2 mmol), 
or N,N-dialkyl-2-(3-thienyl)indol-3-ylglyoxylamide derivatives 47, 48 (0.2 mmol) 
in dry DMF (3 mL). Once hydrogen evolution ceased, an excess of methyl iodide 
(0.6 mmol) was quickly added at 0 °C. The reaction was maintained under stir-
ring at room temperature until the disappearance of starting material (TLC 
analysis with appropriate eluent). The mixture was then dripped into ice and the 
solid precipitated was collected by filtration, dried and subsequently purified by 
recrystallization from toluene. Only the compound 23, N,N-di-n-propyl-N1-
methyl-2-(4-nitrophenyl)indol-3-ylglyoxylamide, was purified by flash chromato-
graphy (CHCl3 as eluent).
38  
Yields, melting points, and spectral data of compounds 39-44 are listed in Table 
4, 49 and 50 in Table 5, while those of compound 23 were reported in litera-
ture.38    
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N,N-di-n-dibutyl-N1-methyl-2-(4-nitrophenyl)indol-3-ylglyoxylamide (38). Yield: 
69%; m. p.: 196-198 °C; 1H-NMR (DMSO-d6, ppm): 0.71-0.81 (m, 6H, 
CH2CH2CH2CH3); 0.92-1.15 (m, 4H, CH2CH2CH2CH3); 1.23-1.44 (m, 4H, 
CH2CH2CH2CH3); 2.92 (2t, 4H, J=7 Hz, CH2CH2CH2CH3); 3.53 (s, 3H, NCH3); 
7.30-7.45 (m, 2H, ArH); 7.70 (d, 1H, J=7 Hz, ArH); 7.80 (d, 2H, J=8 Hz, ArH); 
8.20 (d, 1H, J=7 Hz, ArH); 8.39 (d, 2H, J=8 Hz, ArH).    
 
 
General procedure for the synthesis of: 
N,N-dialkyl-2-(4-aminophenyl)indol-3-ylglyoxylamide derivatives (51-54) 
Pd/C 10% (0.05 g) was added to a suspension of the appropriate N,N-dialkyl-2-
(4-aminophenyl)indol-3-ylglyoxylamide derivatives 1v, 31 or 23, 38 (0.65 mmol) 
in 150 mL of absolute ethanol. The mixture was hydrogenated under stirring for 
5 h at room temperature and reduced pressure (TLC analysis with appropriate 
eluent). Once hydrogen absorption ceased, the catalyst was filtered off and the 
ethanolic solution was evaporated to dryness at reduced pressure. 
All products were purified by recrystallization from toluene. Yields, melting 
points, and spectral data of compounds 51-54 are listed in Table 6.  
 
 
General procedure for the synthesis of: 
N,N-dialkyl-2-(4-hydroxyphenyl)indol-3-ylglyoxylamide derivatives (55-58) 
To a stirred suspension of N,N-dialkyl-2-(4-methoxyphenyl)indol-3-ylglyoxylamide 
derivatives 32, 33 or 39, 40 (0.5 mmol) in 10 mL of dry dichloromethane cooled 
at -10 °C were added dropwise 0.2 mL of BBr3. The mixture was left under stir-
ring for 30 min. at -10 °C, and subsequently at room temperature for 1h under 
nitrogen atmosphere (TLC analysis with appropriate eluent). Finally, the solu-
tion was cooled again, and was added 5 ml of methanol to hydrolyze the excess 
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of BBr3. The solvent was evaporated at reduced pressure, and the solid precipi-
tate was washed several times with methanol.  
The residues obtained were purified by recrystallization from toluene (55, 57) or 
by flash chromatography for compounds 56 and 58 (eluent system, petroleum 
ether/ethyl acetate in 5:5 ratios).     
Yields, melting points, and spectral data of compounds 55-58 are listed in Table 
6.  
 
 
General procedure for the synthesis of: 
4-(3-dialkylaminoglyoxylylindol-2-yl)benzoic acid derivatives (59-64) 
Lithium hydroxide monohydrate (0.3 mmol) was added to a suspension of methyl 
4-(3-dialkylaminoglyoxylylindol-2-yl)benzoate derivatives 35-37 or 42-44 (0.5 
mmol) in 20 mL of a MeOH/H2O (3:1) solution. The mixture was stirred under 
reflux at 80 °C overnight (TLC analysis with appropriate eluent). Subsequently, 
the solid precipitate was eliminate through vacuum filtration, and the solution 
was acidified with HCl dil. 10% to pH 5. The acid precipitated in the solution 
was collected by filtration and generally did not needed any further purification.       
Yields, melting points, and spectral data of compounds 59-64 are listed in Table 
6. 
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